INTRACELLULAR TARGETS OF SPHINGOSINE-1-PHOSPHATE by Strub, Graham Michael
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2009
INTRACELLULAR TARGETS OF
SPHINGOSINE-1-PHOSPHATE
Graham Michael Strub
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Biochemistry, Biophysics, and Structural Biology Commons
© The Author
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/5
 Virginia Commonwealth University  
 
 
 
This is to certify that the dissertation prepared by Graham Michael Strub entitled 
INTRACELLULAR SPHINGOSINE-1-PHOSPHATE INTERACTS WITH AND 
MODULATES THE FUNCTION OF PROHIBITIN-2 has been approved by his or her 
committee as satisfactory completion of the dissertation requirement for the degree of 
Doctor of Philosophy 
 
 
 
 
Dr. Sarah Spiegel, Chair, Department of Biochemistry and Molecular Biology  
 
 
 
Dr. Tomaz Kordula, Department of Biochemistry and Molecular Biology 
 
 
 
Dr. Shawn E. Holt, Department of Pathology 
 
 
 
Dr. Xianjun Fang, Department of Biochemistry and Molecular Biology 
 
 
 
Dr. Joyce Lloyd, Department of Human and Molecular Genetics 
 
 
 
Dr. Jerome Strauss III, Dean, VCU School of Medicine 
 
 
 
Dr. F. Douglas Boudinot, Dean of the Graduate School 
 
 
Friday, July 10 2009 
 
© Graham Michael Strub, 2009 
All Rights Reserved 
 
INTRACELLULAR SPHINGOSINE-1-PHOSPHATE INTERACTS WITH AND 
MODULATES THE FUNCTION OF PROHIBITIN-2 
 
A Dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
 
by 
 
GRAHAM MICHAEL STRUB 
Master of Science, Virginia Commonwealth University, 2003 
Bachelor of Science, University of Richmond, 2001 
 
Director: DR. SARAH SPIEGEL 
CHAIR, DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY 
 
 
 
 
 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
July, 2009
   
 ii 
Acknowledgement 
 
 
 
I would like to acknowledge the following people who helped in the completion of this 
project, directly or indirectly: Dr. Sarah Spiegel, Dr. Sheldon Milstien, Dr. Tomek 
Kordula, Dr. Frank Fang, Dr. Shawn Holt, Dr. Joyce Lloyd, Dr. Nitai Hait, Dr. Jie Liang, 
Dr. Mike Maceyka, Dr. Edward Lesnefsky, Melanie Palliard, Dr. Ludovic Gomez, Dr. 
Qun Chen, Dr. Scott Henderson, Judy Williamson, Dr. Dmitri Kapitinov, Dr. Sergio 
Alvarez, Dr. Carol Oskarizian, Dr. Steve Paugh, Dr. Aki Mikami, Dr. Heidi Sankala, Dr. 
Kuzhuvelil B. Harikumar, Dr. Magdalena Szelag, and Dr. Andy Larner. 
 
I would like to further acknowledge Dr. Sarah Spiegel for her outstanding mentorship, 
scientific insight, and confidence in my abilities in the pursuit of this degree. 
 
I would also like to further acknowledge Dr. Shawn Holt for his mentorship during my 
Master of Science training, as this provided the fundamental skill set necessary to pursue 
further research. 
 
Finally I would like to acknowledge my friends and family for their support, both 
emotional and financial, and their patience with me as I continue in this long training 
   
 iii 
path: Amie Strub, Linda Strub, Peter Strub, Tom Gavin, Vera Strub, Margaret Richter, 
Judy Williams, and Neil Williams. 
 
 
 
The Road goes ever on and on 
Down from the door where it began. 
Now far ahead the Road has gone, 
And I must follow, if I can, 
Pursuing it with eager feet, 
Until it joins some larger way 
Where many paths and errands meet. 
 And whither then? I cannot say. 
 
   J.R.R Tolkien 
 
 
But who can unlearn all the facts that I've learned 
As I sat in their chairs and my synapses burned 
And the torture of chalk dust collects on my tongue 
Thoughts follow my vision and dance in the sun 
All my vasoconstrictors they come slowly undone 
Can't this wait till I’m old? 
Can't I live while I'm young? 
 
   Trey Anastasio 
 
  iv 
Table of Contents 
Page 
Acknowledgements ............................................................................................................. ii 
List of Figures  .................................................................................................................... vi 
Abstract  .................................................................................................................. viii 
Chapter  
 1 Introduction ........................................................................................................ 10 
1.1 Introduction .......................................................................................... 10 
1.2 Sphingolipid Metabolism ..................................................................... 11 
1.3 S1P Receptors ....................................................................................... 14 
1.4 S1P1 Receptor ....................................................................................... 15 
1.5 S1P2 Receptor ....................................................................................... 17 
1.6 S1P3 Receptor ....................................................................................... 17 
1.7 S1P4-5 Receptors ................................................................................... 18 
1.8 Sphingosine Kinase Type I (SphK1) .................................................... 19 
1.9 Sphingosine Kinase Type II (SphK2) ................................................... 21 
1.10 SphK1 vs. SphK2 ............................................................................... 22 
1.11 Evidence for intracellular targets of S1P ............................................ 26 
1.12 Intracellular S1P in yeast .................................................................... 27 
1.13 Intracellular S1P in plants................................................................... 28 
1.14 Intracellular S1P in mammalian cells ................................................. 28 
1.15 Hypothesis and specific aims of current study ................................... 34 
   
 v 
 
2 Materials and Methods .................................................................................... 37 
3 Results ............................................................................................................. 50 
3.1 PHB2 binds S1P in the nucleus ............................................................ 50 
3.2 S1P augments E2-mediated transcriptional repression in the nucleus . 60 
3.3 Mitochondrial S1P-PHB2 interaction and function.............................. 63 
4 Discussion ....................................................................................................... 89 
4.1 Summary of Results.............................................................................. 89 
4.2 Actions of prohibitins ........................................................................... 91 
4.3 Prohibitin structure ............................................................................... 92 
4.4 Prohibitin localization........................................................................... 94 
4.5 Prohibitin function within the nucleus.................................................. 97 
4.5.1 PHB1 in the nucleus .......................................................................... 97 
4.5.2 PHB2 in the nucleus .......................................................................... 99 
4.6 Lipid signaling in the nucleus ............................................................. 103 
4.7 Prohibitins in the mitochondria .......................................................... 105 
4.8 Concluding remarks ............................................................................ 110 
 
Literature Cited ............................................................................................................... 113 
Appendices ...................................................................................................................... 153 
A S1P binds to HDAC1 and HDAC2 ............................................................... 153 
Vita .................................................................................................................................. 154 
   
 vi 
 
List of Figures 
 
Page 
Figure A: Schematic of phospholipid metabolism ............................................................ 12 
Figure B: SphK1 and SphK2 structural domains .............................................................. 23 
Figure C: S1P exerts both intracellular and extracellular effects ...................................... 36 
Figure D: Prohibitins and their assembly into complexes. ............................................... 93 
Figure E: Potential model of S1P-PHB2 transcriptional repression of E2-stimulated genes.
 ......................................................................................................................................... 103 
Figure F: Potential model for PHB2-S1P function in the assembly of electron transport 
chain subunits. ................................................................................................................. 110 
Figure 1: S1P binds to proteins from MCF7 cells. ........................................................... 51 
Figure 2: Identification of PHB2 as a S1P binding protein .............................................. 53 
Figure 3: PHB2 specifically binds S1P ............................................................................. 55 
Figure 4: PHB2 binds to immobilized S1P ....................................................................... 56 
Figure 5: S1P is bound to PHB2 in cells ........................................................................... 58 
Figure 6: Ectopically expressed SphK2 interacts with PHB2 / HDAC1 in MCF7 nuclei 59 
Figure7: S1P and PHB2 suppress E2-mediated transcription ........................................... 62 
Figure 8: Depletion of SphK2 increases ERE-Luciferase expression .............................. 64 
Figure 9: Depletion of SphK2 augments endogenous E2-mediated transcription ............ 65 
   
 vii 
Figure 10: PHB2 and SphK2 are present in mitochondria and nuclei .............................. 67 
Figure 11: Mitochondrial PHB2 binds S1P ...................................................................... 68 
Figure 12: Mass spectrometric analysis of LCB lipids in mouse liver fractions .............. 70 
Figure 13: Mass spectrometric analysis of CSL lipids in mouse liver fractions ............... 71 
Figure 14: Mass spectrometric analysis of LCB lipids in mouse heart fractions and intact 
cardiomyocytes ................................................................................................................. 73 
Figure 15: S1P is bound to endogenous mitochondrial PHB2 .......................................... 74 
Figure 16: Depressed mitochondrial respiration in SphK2
-/-
 mice ................................... 76 
Figure 17: Reactive oxygen species generation is decreased in SphK2
-/-
 mice ................ 78 
Figure 18: Calcium retention capacity is unaltered in SphK2
-/-
 mitochondria ................. 79 
Figure 19: SphK2
-/-
 display an aberrant complex IV via blue native page  ...................... 81 
Figure 20: Electron micrographs of wildtype and SphK2
-/-
 myocardium ......................... 83 
Figure 21: Electron micrographs of wildtype and SphK2
-/-
 liver sections ........................ 84 
Figure 22: Electron micrographs of wildtype and SphK2
-/-
 purified liver mitochondria. . 85 
Figure 23: PHB2-COXIV interaction is ablated in SphK2
-/-
 mouse myocardial 
mitochondria ..................................................................................................................... 87 
Figure 24: Cytochrome C oxidase activity is impaired in SphK2
-/-
 mice and can be restored 
with exogenous S1P .......................................................................................................... 88 
 
  
   
 viii 
 
 
Abstract 
 
 
 
INTRACELLULAR SPHINGOSINE-1-PHOSPHATE INTERACTS WITH AND 
MODULATES THE FUNCTION OF PROHIBITIN-2 
By Graham Michael Strub, M.S. 
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2009 
 
Major Director:  Sarah Spiegel 
Chair, Biochemistry and Molecular Biology 
 
 
 
 
The bioactive lipid mediator sphingosine-1-phosphate (S1P) has emerged as a key 
regulator of a variety of important physiological functions, including cell growth, cell 
survival, cell motility, angiogenesis, lymphocyte trafficking, and mast cell function. S1P is 
formed by two different sphingosine kinases (SphKs) and binds to a family of 5 
differentially expressed G-protein coupled receptors (S1PRs). The majority of research to 
date has focused on the activation of these receptors, but there is compelling evidence to 
suggest that S1P exerts intracellular functions independent of S1PRs. However no bona 
fide intracellular targets of S1P have been identified. Here, we identify prohibitin-2 
   
 ix 
(PHB2), a transcriptional repressor and mitochondrial chaperone protein, as a novel 
intracellular binding protein for S1P. We demonstrate that this binding is specific and 
occurs in both the nucleus of cells as well as the mitochondria. PHB2-S1P interaction in 
the nucleus of cells augments PHB2 function as an estradiol-mediated transcriptional 
repressor, and depletion of nuclear S1P levels inhibits PHB2’s ability to repress estradiol 
stimulated genes in human cancer cells. PHB2 also assists in the proper import and folding 
of mitochondrial proteins, including the assembly of electron transport chain complexes. In 
this study we show that PHB2 and SphK2 are localized in the mitochondria and that S1P in 
the mitochondria also binds PHB2. Mitochondria from SphK2
-/-
 hearts have significantly 
reduced levels of mitochondrial S1P and display impaired oxygen consumption, aberrant 
cytochrome-c oxidase assembly, and decreased cytochrome-c oxidase enzyme activity that 
can be restored with the addition of S1P. These results point to novel actions of 
intracellular S1P and provide new insights on how both PHB2 and SphK2 function inside 
the nucleus and mitochondria to regulate estrogen-dependent transcription and respiration, 
respectively. 
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CHAPTER 1: Introduction 
 
1.1 Introduction:  
Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator with crucial roles in a 
wide variety of cellular functions across a broad range of organisms (1). A simple 
molecule in structure, S1P function is complex. The formation of S1P is catalyzed by one 
of two sphingosine kinases (SphK1 and SphK2), which have differential cellular 
distributions as well as both overlapping and opposing functions, and which are activated 
by many different stimuli. S1P can act on a family of G-protein coupled receptors, 
designated S1PRs, which are also differentially expressed in different cell types, and this 
differential expression influences the cellular response to S1P. In addition to acting on 
receptors located on the plasma membrane, S1P can also function inside the cell, 
independently of the S1PRs (2). It also appears that both the intracellular location and the 
isotype of sphingosine kinase activated are major determinants of how cells respond to S1P 
(3).  
In just over a decade, S1P has emerged as a key regulator of numerous physiological 
functions, including cell growth and survival, angiogenesis, cell motility and migration, 
and lymphocyte trafficking. S1P promotes cell growth and inhibits apoptosis, while its 
precursors, ceramide and sphingosine, typically inhibit cell growth and induce apoptosis. 
Therefore, the cellular balance of these three sphingolipid metabolites, the “sphingolipid 
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rheostat”, is of crucial importance in regulating cell fate. Moreover, sphingolipid 
metabolism has been found to be dysregulated in many human diseases, including cancer, 
inflammation, atherosclerosis, and asthma. S1P is produced intracellularly by two 
sphingosine kinases (SphK1 and SphK2) and is the ligand for a family of five G protein-
coupled receptors (S1PRs), termed S1P1-5. These receptors differentially couple to various 
heterotrimeric G-proteins, which accounts for the diverse, sometimes opposing, effects of 
S1P. In addition to the effects mediated through the S1P cell surface receptors, there are 
some actions of S1P that appear to be independent of the known S1PRs. The primary goal 
of this project is to identify the intracellular targets of S1P and characterize the 
mechanisms by which S1P exerts its intracellular functions. 
 
1.2 Sphingolipid Metabolism 
 
Sphingolipids are ubiquitous components of the lipid bilayer of eukaryotic cells. Like 
glycerolipids, numerous agonists regulate sphingolipid metabolism to generate signaling 
molecules, including ceramide (N-acyl sphingosine), sphingosine and sphingosine-1-
phosphate (S1P) (2,4,5). Figure A (4) illustrates these processes. Ceramide, the backbone 
of all sphingolipids, is produced both by de novo synthesis and by turnover of 
sphingolipids, such as hydrolysis of sphingomyelin by sphingomyelinases. De novo 
synthesis at the endoplasmic reticulum (ER) is initiated by condensation of serine and 
palmitoyl-CoA catalyzed by serine palmitoyltransferase (SPT). The 3-ketosphinganine  
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Figure A: Schematic of sphingolipid metabolism (adapted from (4)). The formation of 
ceramide occurs through 4 mechanisms (de novo: purple; sphingomyelin hydrolysis: blue; 
cerebrocide hydrolysis: aqua; formation from S1P: orange). C1PP, ceramide-1-phosphate 
phosphatase; CRS, cerebrosidase; CK, ceramide kinase; CS, ceramide synthase; DAG, 
diacylglycerol; DES, dihydroceramide desaturase; GCS, glucosylceramide synthase; PC, 
phosphatidylcholine; S1PP, S1P phosphatase; SMS, sphingomyelin synthase; SMase, 
spingomyelinase; SPT, serine palmitoyl transferase. 
 
 
 
   
 13 
formed is rapidly reduced to dihydrosphingosine, which is subsequently N-acylated by one 
of a family of six (dihydro)ceramide synthases (CerS, formerly referred to as LASS) to 
form dihydroceramide, with the CerSs having differing but overlapping preferences for 
acyl chains from 16 to 26 carbons long. Finally, a 4-5 trans double bond is introduced in 
the sphingoid base to produce ceramide. Ceramide is then trafficked from the ER to the 
Golgi, where a variety of head groups are added, forming sphingolipids. After removal of 
these head groups during catabolism, deacylation of ceramide by ceramidases yields 
sphingosine, the most common sphingoid base in mammals. It is important to note that 
sphingosine are not produced de novo and are only formed by catabolism of sphingolipids. 
These sphingoid bases can be re-utilized for complex sphingolipid biosynthesis or 
phosphorylated by two sphingosine kinases (SphK1 and SphK2) to form S1P or dihydro-
S1P. S1P can be degraded either by reversible dephosphorylation to sphingosine by 
phosphatases, including lysosomal phosphatases, members of the LPP family of lipid-
specific phosphatases, and two S1P-specific phosphatases, termed SPP1 and SPP2 
(reviewed in (6)), or degraded by irreversible cleavage to ethanolamine phosphate and 
hexadecenal by S1P lyase (SPL) (7). 
Ceramide and sphingosine, the precursors of S1P, are important regulatory components 
of stress responses, typically inducing growth arrest and apoptosis (4,5). In contrast, S1P 
has been implicated in motility and cytoskeletal rearrangements, formation of adherens 
junctions, proliferation, survival, angiogenesis, and the trafficking of immune cells (2,8-
10). Thus, the dynamic balance between S1P and ceramide, and the consequent regulation 
of opposing signaling pathways, is an important factor that determines cell fate (11). S1P 
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produces many of its effects by acting as a ligand for a family of five G-protein coupled 
receptors (GPCRs), called S1P1-5, discussed below. However, though intracellular targets 
for both ceramide and sphingosine have been identified, indicating they are both bona fide 
second messengers, intracellular targets for S1P have remained elusive.  
 
1.3 S1P Receptors 
 
S1P is a ligand for five specific GPCRs, S1P1-5, formerly called endothelial 
differentiation gene (EDG) receptors, which are differentially expressed in different 
tissues. The cell type specific expression of S1PRs, as well as their differential coupling to 
different G proteins, explains the diverse signaling of S1P (12). As mentioned above, many 
stimuli, including hormones, immunoglobulin receptor ligation, growth factors, and 
cytokines, activate cytosolic SphKs and the production of S1P which is required for the 
full activity of these agonists. In many cases, the S1P produced activates cell surface 
S1PRs in a paracrine and/or autocrine manner (reviewed in (13)). Indeed, many of the 
downstream effects of these stimuli require transactivation of one or more S1PRs, also 
called “inside-out” signaling. For example, in MCF7 cells, estradiol stimulates ERK1/2 
through a mechanism that requires at least two autocrine signaling loops (14). In the first 
loop, estradiol stimulates SphK1 and formation of S1P leading to activation of S1P3. In the 
second loop, S1P3 activates the metalloproteinase MMP-9, which in turn releases EGF 
from the EGF-heparin binding protein and activates EGFR, finally leading to ERK1/2 
phosphorylation (14). How transactivation of S1PRs is accomplished is an intriguing 
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puzzle as the SphKs and S1P production occurs on the cytosolic side of the plasma 
membrane and S1PRs bind S1P on the exoplasmic side. While it has been suggested that 
SphK proteins themselves may be secreted and produce S1P extracellularly (15), it has 
been convincingly shown that the ABCC1 transporter mediates S1P secretion from mast 
cells (16). Moreover, S1PR transactivation is not only regulated by S1P secretion, but its 
cellular levels are also important, as decreasing S1P levels by overexpression of SPP1 
inhibits transactivation (17), while decreasing S1P degradation by inhibition of SPL 
promotes it (18). Such inside-out transactivation loops may be a general phenomenon, as 
chemotactic signals for neutrophils acting through their receptors induce secretion of ATP 
that then locally activates cell surface nucleotide receptors to coordinate directed cell 
migration (19). 
 
1.4 S1P1 Receptor  
 
S1P1 is ubiquitously expressed, with high levels in brain, lung, spleen, cardiovascular 
system, and kidney. It was originally identified as an orphan GPCR involved in 
differentiation of endothelial cells (20). Since its discovery, many of the important 
physiological functions of S1P have been attributed to ligation of this receptor. It is now 
known that S1P1 plays a key role in angiogenesis, as its deletion in mice is embryonic 
lethal due to hemorrhage. This phenotype results from incomplete vascular maturation due 
to the failure of smooth muscle cells and pericytes to migrate and envelop nascent 
endothelial tubes (21). Endothelial cell conditional S1P1 knockout mice have been 
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generated using the Cre/Lox system, and these mice display the same vascular deficiencies, 
suggesting that S1P1 receptors on endothelial cells are also responsible for vessel coverage 
by smooth muscle cells (22). S1P1 also plays an important role in maintenance of 
endothelial and epithelial barrier integrity by working in conjunction with S1P2 and S1P3 
to increase vascular integrity (23-25). Disruption of endothelial barriers leads to increased 
vascular permeability, often found in tumors and in inflammation. Silencing of S1P1 
expression with siRNA blocks barrier enhancement, determined by transendothelial 
monolayer electrical resistance, while silencing of S1P3 inhibits vascular disruption (25). 
These experiments also identified the downstream signaling molecules Akt and Rac as 
effectors of S1P1 actions on vascular integrity (25). A role for S1P1 in vascular integrity 
has also been demonstrated in vivo (26-29), and experiments using a S1P1 selective 
antagonist demonstrated that S1P1 is crucial in maintaining vascular tone (30). Of 
particular interest are the conditional SphK1/SphK2 double knockout mice, which have 
normal vascular integrity despite having over 100-fold lower plasma S1P levels than wild 
type mice (31), suggesting that even a very low level of S1P is sufficient as long as S1P1 
expression is normal.  
S1P1 is also intimately involved in immune cell function. In particular, its expression is 
required for lymphocyte egress from lymph nodes. Resting T and B cells express primarily 
S1P1, and its downregulation or deletion results in lymphopenia due to the inability of 
lymphocytes to exit from the lymph nodes (32,33). Additionally, transplantation of S1P1 
deficient thymocytes and lymphocytes into normal mice results in their sequestration in 
lymph nodes and Peyer’s patches. Moreover, T-cells overexpressing S1P1 preferentially 
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distribute into blood (34). These results confirm that S1P1 controls lymphocyte 
recirculation. 
 
1.5 S1P2 Receptor  
 
S1P2 is also widely expressed in a variety of different cell types. Unlike S1P1 knockout 
mice, S1P2 deficient mice do not demonstrate any striking abnormalities, although they 
have been reported to develop sporadic seizures between 3-7 weeks of age (35). 
Neocortical pyramidal cells from these mice also display an increase in excitability (35). In 
addition, S1P2
-/-
 mice are deaf, indicating that S1P2 is required for proper development of 
the auditory and vestibular systems (36,37). S1P2 is also required for proper degranulation 
of mast cells (38). S1P2 is generally considered to be a repellant receptor as its activation 
inhibits cell migration and appears to work in opposition to S1P1 and S1P3, both of which 
enhance cell migration (39). Similarly, activation of S1P2 activates ROCK/Rho and leads 
to increases in vascular permeability (24). Finally, although the visceral organs of S1P2
-/-
 
mice develop normally, expression of S1P2 promotes liver tissue remodeling in response to 
acute injury (40). 
 
1.6 S1P3 Receptor  
 
Much like the lack of phenotypic effects of deletion of S1P2, deletion of S1P3 in mice 
does not generate any obvious phenotype. S1P3 is expressed in the cardiovascular system, 
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lungs, kidney, intestines, spleen, and cartilage (41). Simultaneous knockouts of both S1P2 
and S1P3 increases perinatal lethality, but not to a great extent (42). However, the triple 
knockout of S1P1-3 leads to embryonic lethality due to massive vascular deficiencies, 
perhaps even worse than those resulting from knockout of S1P1 alone (43). S1P3 is also an 
important regulator of vascular permeability signaling through the downstream effectors 
ROCK and Rho (24). A clear role of S1P3 has also been demonstrated in the regulation of 
heart rate (44) as S1P3 expression is localized to myocytes and perivascular smooth muscle 
cells, and its activation results in bradycardia and hypertension. 
 
1.7 S1P4-5 Receptors  
 
S1P4-5 have much narrower patterns of expression than the dominant S1P1-3 receptors, 
localizing in human leukocytes, NK cells, airway smooth muscle cells and white matter of 
CNS tracts (45-48). S1P4 is primarily expressed in lymphoid tissues, including the thymus, 
spleen, bone marrow, appendix, and peripheral leukocytes (49). S1P4 directly couples to 
Gαi and Gα12/13 subunits of trimeric G proteins, and Jurkat cells overexpressing S1P4 
display enhanced pertussis toxin-sensitive cell motility in the absence of S1P (50). S1P4 
stimulation also activates the mitogen activated-protein kinases ERK1/2, activates 
phospholipase C, and modulates the opening of intracellular calcium stores (51,52). 
Stimulation of S1P4 ectopically expressed on CHO-K1 cells induced cytoskeletal 
rearrangements and cell rounding, as well as its internalization following S1P stimulation 
(50). Whether or not S1P4 has a role in cell motility remains unclear. In D10G4.1 mouse 
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Th2 cells and EL4.IL-2 mouse T cells lacking endogenous S1P receptors but transfected 
with S1P4, its activation failed to transduce chemotactic responses (53). These cells also 
displayed enhanced secretion of IL-10 and decreased proliferation in response to S1P (53).  
S1P5 is highly expressed in oligodendrocytes (47); however, silencing of S1P5 
expression does not inhibit myelination or produce any other obvious phenotype in these 
cells (54). Binding of S1P to S1P5 induces phosphatase-dependent inhibition of ERK1/2, 
resulting in an anti-proliferative phenotype (46,55,56). In addition, stimulation of rat 
oligodendrocytes with PDGF increases S1P1 expression with a concomitant 
downregulation of S1P5, resulting in an amplified mitogenic response (57). A recent report 
has demonstrated that S1P5 is present in natural killer cells (NK). Mice deficient in S1P5 
display aberrant NK cell homing and mobilization of NK cells to inflamed organs (48). 
Finally, despite a multitude of studies focusing on physiological functions of S1PRs, some 
actions of S1P resulting from activation of SphKs are independent of S1PRs (discussed 
below). 
 
1.8 Sphingosine Kinase Type I (SphK1) 
 
SphK1a is a 48 kDa splice variant that was cloned utilizing peptide sequences from 
SphK1 purified to homogeneity from rat kidneys (58). Most investigations of the role of 
SphK1 have focused on SphK1a, the major splice form, although two N-terminal extension 
splice variants have been described in humans, SphK1b (+14 aa) and SphK1c (+86 aa), all 
with similar enzymatic properties (59). SphK1 isoforms are predominantly cytosolic but 
   
 20 
have slightly different subcellular distributions, with SphK1b and SphK1c having greater 
plasma membrane localization (15). Interestingly, extracellular secretion of SphK1a, by 
unknown mechanisms through a Golgi-independent route has been described (15), though 
the biological significance of this is not yet clear. SphK1 was initially purified in part 
based on its ability to bind to a calcium-calmodulin column (60). Subsequently, it was 
shown that SphK1 has a calmodulin binding site between residues 191-206, the mutation 
of which blocks agonist-induced SphK1 translocation to the plasma membrane but not its 
activation (61). An important advance in understanding regulation of SphK1 was the 
demonstration that SphK1 is phosphorylated on Ser225 by ERK1/2 (62), which was 
necessary but not sufficient for its targeting to the plasma membrane (63). SphK1 has been 
shown to physically interact with a number of proteins that may affect its cellular 
localization, including RPK118 (64), PECAM-1 (65), Acy1 (66), and d-catenin/NPRAP 
(67), among others. SphK1 is activated by diverse stimuli, including hormones, growth 
factors, immunoglobulin receptor crosslinking, cytokines, chemokines, and lysolipids, 
including S1P (2). Functionally, numerous studies have demonstrated a role for S1P 
produced by SphK1 in protection of cells from apoptosis, promotion of cell growth, 
stimulation of motility and tumorigenesis, and as an essential component of many 
signaling pathways, activating kinases, phospholipases, and inducing calcium release 
(reviewed in (2,9,68,69)). Indeed, many of the pro-growth and anti-apoptotic effects 
observed by exogenous addition of S1P can be reproduced by overexpression of SphK1. 
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1.9 Sphingosine Kinase Type II (SphK2) 
 
Much less is known about SphK2, which was cloned in mammalian cells based on its 
homology to SphK1 (70). SphK2 has two splice variants. The smaller, originally cloned 
SphK2-S, contains 618 amino acids, and the N-terminally extended SphK2-L, consists of 
654 amino acids (71). SphK2-L is expressed in human cells but not in mice, and is 
reported to be the predominant SphK2 mRNA in most cell lines and tissues except brain 
and kidney. SphK1 and SphK2 have similar abilities to phosphorylate endogenous 
substrates, but SphK2 is mainly responsible for phosphorylation of the immunosuppressive 
pro-drug, FTY720 (32,72,73). SphK2 was found to be a two hybrid interactor with the 
cytoplasmic domain of the IL-12 receptor β1, and SphK2 overexpression enhanced IL-12-
mediated signaling (74). SphK2 also binds calmodulin at a site that is conserved between 
the SphKs, although unlike SphK1, interaction with calmodulin does not alter SphK2 
localization (61). SphK2 contains a putative BH3 domain which has been shown to 
contribute to the ability of overexpressed SphK2 to induce apoptosis in a variety of cell 
types (75). In contrast to SphK1, only a few agonists have been shown to activate SphK2, 
including EGF (76), IgE receptor crosslinking (77), and IL-1β and TNFα (78). Of note, 
EGF activates SphK1 and induces phosphorylation on Ser-351 and Thr-578, both 
dependent on ERK1 (79). Moreover, this phosphorylation was required for SphK2-
enhanced cell migration towards EGF (79). Intriguingly, although SphK2 expression 
typically inhibits growth, promotes apoptosis and chemosensitizes several cell types 
(71,75,80,81), SphK2 protects MCF7 breast cancer cells and HCT116 colon cancer cells 
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from doxorubicin-induced apoptosis by a pathway mediated by p53-independent 
upregulation of p21/WAF1/CIP1 (82). 
 
1.10 SphK1 vs. SphK2 
 
Even though mice with single knockouts of SphK1 and SphK2 are viable with few 
obvious phenotypes, suggesting that the SphKs have redundant functions, the kinases 
exhibit many differences in a variety of experimental systems. Indeed, several studies have 
shown that the two SphKs in yeast, Lcb3p and Lcb4p, do not complement one another (e.g. 
(83)), although this may be due to the much higher activity of Lcb4p. Moreover, both 
SphKs, in yeast as well as mammals, have overlapping but distinct subcellular 
localizations, suggesting that they may interact with different proteins and/or lipids and 
utilize different sphingoid base substrate pools. The first clues that eukaryotic SphK1 and 
SphK2 may differ functionally came from the observations that, in contrast to many 
reports demonstrating a pro-growth, anti-apoptotic role for SphK1, SphK2 overexpression 
induced growth arrest and cell death (71,75,80). Consistent with these results, SphK1 
decreased, while SphK2 increased, the sensitivity of several different cell lines to a variety 
of chemotherapeutic drugs (75,81). However, other studies have revealed that SphK2 
knockdown reduced proliferation of glioblastoma cell lines (84). The cell culture results 
demonstrating a role for SphK1 in cell growth and apoptosis are likely 
pathophysiologically relevant, as SphK1 has been demonstrated to be overexpressed in a 
number solid tumors, including breast, ovary, kidney, brain, stomach, and kidney (84,85). 
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Perhaps because of its role as a promoter of apoptosis, SphK2 but not SphK1 was reported 
to be responsible for the secretion of S1P during apoptosis of Jurkat T cells induced by 
staurosporine (86). Conversely, in hematopoietic cancer cells, it was recently shown that 
SphK1 produced the S1P that was secreted in response to doxorubicin-induced apoptosis 
(87). 
 
Figure B: SphK1 and SphK2 structural domains. NLS: nuclear localization 
sequence. C1-C5: conserved domains. TM: hydrophobic stretches. 
 
The differential effects of the two SphKs on cell fate are due in part to their different 
roles in regulating ceramide levels. SphK1 expression decreases ceramide levels, likely by 
inhibiting ceramide synthases (3,88). Conversely, SphK2 expression increases ceramide 
levels by increasing the salvage of sphingoid bases (3). In a pathway that is conserved in 
yeast (83), exogenous sphingoid bases must first be phosphorylated by a specific SphK 
(Lcb4p or SphK2), then dephosphorylated by a specific SPP (Lcb3p or SPP1) (89,90). This 
cycle enables cells to re-acylate sphingoid bases to ceramides and likely represents control 
points that cells use to regulate the amount of ceramide and sphingolipids at the levels of 
de novo synthesis (SphK1) and salvage of sphingoid bases (SphK2). SphK1 and SphK2 
also appear to have different roles in the uptake of S1P, with SphK1 but not SphK2 
cooperating in another phosphorylation/dephosphorylation cycle that utilizes cell surface 
LPP-1 to promote sphingoid base uptake (91). 
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Differential effects of SphK1 and SphK2 are also apparent in transduction of signals 
from cell surface receptors. Perhaps because it was cloned first and thus is more well 
studied, SphK1-dependent formation of S1P has been found to be an important component 
of numerous receptor signaling pathways, but even in cases where participation of both 
SphK1 and SphK2 have been examined, it is still SphK1 that is typically involved. To cite 
a few examples, estradiol activates SphK1, but not SphK2, ultimately leading to EGFR 
activation (14); similarly, VEGF-induced activation of ERK1/2 in T24 bladder cancer cells 
requires SphK1 but not SphK2 (92); moreover, targeting SphK1 but not SphK2 with 
siRNA also blocks TNFα-induced COX-2 induction and PGE2 secretion (93).  
Many studies have demonstrated a role for S1P and S1PRs in cell motility (reviewed in 
(94)), and SphK1, but not SphK2, has often been reported to be the source of S1P. For 
example, EGF stimulates the activity and lamellipodial translocation of SphK1 in MCF-7 
cells, and overexpression of SphK1 enhances migration towards EGF (95). EGF also has 
been shown to stimulate both SphK1 and SphK2 in HEK 293 cells, but only SphK1 was 
required for EGF-induced motility (76). The lack of requirement for SphK2 in these cells 
is the more remarkable because SphK2 was already localized at the plasma membrane, and 
suggests that a SphK may need to be targeted to a specific sub-compartment of the plasma 
membrane, perhaps in close proximity to its substrate and the S1PRs and/or perhaps 
specific S1P transporter(s). Intriguingly, EGF also stimulates both SphK1 and SphK2 in 
MDA-MB-453 cells, but in these breast cancer cells, both SphKs are required for EGF-
induced motility (76). 
   
 25 
The roles of S1P in the immune system are complex, and deciphering the SphKs 
involved is a challenging task. It has been shown in rat RBL-2H3 mast cells that SphK1, 
but not SphK2, is required for degranulation in response to IgE receptor crosslinking (38). 
In contrast, in mouse bone marrow-derived mast cells, both SphK1 and SphK2 are 
activated by IgE receptor crosslinking in a Fyn-dependent manner (77). Interestingly, 
SphK1 and SphK2 have different requirements for effectors downstream of Fyn, 
suggesting other levels of regulation of SphK activation. These authors also showed that 
exogenous S1P could only partially restore degranulation to Fyn
-/-
 mice, hinting at an 
intracellular role for S1P (discussed below). This group later took advantage of Sphk1
-/-
 
and Sphk2
-/-
 double knockout mice to demonstrate that in fetal liver-derived and bone 
marrow-derived mast cells, SphK2, but not SphK1, was responsible for IgE receptor 
triggered degranulation and cytokine release (96). However, in a passive systemic 
anaphylaxis model, they found that Sphk2
-/-
 mice fared as well or slightly worse than wild-
type mice in terms of increased plasma histamine levels. Conversely, Sphk1
-/-
 mice had 
reduced plasma histamine levels. Sphk1
-/-
 mice also had reduced plasma S1P levels 
compared to wild type and Sphk2
-/-
 mice, and the intensity of the histamine released 
positively correlated with circulating S1P levels. The triple allele knockout SphK1+/-
SphK2
-/-
 mice had the lowest histamine responses and had plasma S1P levels as low as the 
Sphk1
-/-
 mice. Thus, mast cell function in mice is determined both by SphK2 in mast cells 
(intrinsic S1P) and circulating S1P levels determined by non-mast cell SphK1 (extrinsic 
S1P). In contrast, in both human LAD2 mast cells (97) and human umbilical cord blood-
derived mast cells (98), knockdown of SphK1 expression decreased degranulation, 
   
 26 
cytokine release, and motility in response to IgE/antigen (99). Conversely, SphK2 was 
dispensable for antigen-induced degranulation, motility, or release of most cytokines (99). 
S1P likely also plays important roles in other types of immune cells, although neutrophil 
function in cells isolated from SphK1
-/-
 or SphK2
-/-
 mice, or even in the whole animals 
themselves, showed little observable differences between the knockouts and wild type. The 
SphK2
-/-
 mice did have increased disease progression in a lung infection model (100). 
Differences between mouse and human immune systems remain to be resolved, but will 
likely require SphK isozyme-specific inhibitors to elucidate the roles for the SphK1 and 
SphK2 in mast cell functions and development. 
 
1.11 Evidence for intracellular targets of S1P 
 
As discussed above, cellular levels of S1P are controlled both by its synthesis and by 
its degradation. S1P can be degraded either by dephosphorylation back to sphingosine or 
irreversibly degraded by SPL to ethanolamine phosphate and fatty aldehyde. In fact, the 
latter is the only pathway in eukaryotic cells for degradation of sphingoid bases. Thus, S1P 
formation and subsequent degradation by SPL is one means for decreasing sphingolipid 
levels within the cell. Intriguingly, S1P is also an intermediate in the formation of 
sphingolipids from salvaged sphingoid bases. Though these pathways regulating 
sphingolipid levels demonstrate a central role for S1P, emerging evidence from yeast, 
plants, and mammals points to S1P as a classical, intracellular second messenger. 
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1.12 Intracellular S1P in Yeast 
 
The yeast genome does not encode a recognizable cell surface receptor for S1P and 
exogenous S1P does not affect yeast growth (101). Thus, any role for S1P in yeast 
physiology must therefore be intracellular. While no direct target for S1P has been found, 
S1P does indeed have intracellular functions in yeast. First, it has been demonstrated that 
yeast cells with deletions of S1P phosphatase (lcb3/ysr2/lbp1) and SPL (dpl1) genes 
accumulate large amounts of S1P and are non-viable or very slow growing. This growth 
arrest can be can be rescued if the major yeast SphK (lcb4) is deleted, indicating that 
intracellular S1P suppresses yeast cell growth (102,103). Indeed, sphingosine itself induces 
growth arrest in yeast, and this effect can be can be blocked by mutational inactivation of 
SphK (101). The growth inhibition may be due to elevated levels cytosolic calcium, as S1P 
has been shown to increase intracellular calcium levels (104). In contrast, while heat 
shock-induced cell cycle arrest is mediated by the sphingoid base itself (105), S1P has 
been linked to enhanced protection from heat shock by unknown mechanisms. First, heat 
shock increases SphK activity (101) and S1P accumulation (106), suggesting a functional 
role for S1P in heat shock responses. Preventing S1P metabolism by deletion of either the 
S1P phosphatase Lcb3p (107,108) or SPL (106) led to enhanced levels of S1P and 
increased heat shock tolerance. Moreover, mutational inactivation of SphK reversed the 
protective effect of SPL deletion (101). That deletion of either an S1P phosphatase or the 
S1P lyase promotes heat tolerance indicates that S1P has direct actions, rather than merely 
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functioning as a metabolic intermediate. However, a molecular target of S1P has not yet 
been found in yeast. 
 
1.13 Intracellular S1P in Plants 
 
Abscisic acid is a plant hormone responsible for mediating responses to drought 
conditions such as closure of stomata to prevent water loss. It was recently demonstrated 
that drought increased S1P levels in plants, and that abscisic acid-induced stomatal closure 
was reduced by SphK inhibitors (109). Subsequently, it was shown that abscisic acid 
activated SphK in Arabidopsis (110). Intriguingly, these authors showed that the effects of 
S1P on stomatal openings were dependent on the single canonical Gα protein in plants, 
GPA1. This finding suggests that S1P might be acting through plant GPCRs. However, 
Arabidopsis has only one GPCR-like protein, designated GCR1, which is not homologous 
to the known S1PRs, does not bind phosphorylated sphingoid bases, and GCR1 mutants 
are hypersensitive to S1P-induced stomatal closure (111). Thus, intracellular S1P is likely 
responsible for closure of stomatal apertures and drought responses in plants. 
 
1.14 Intracellular S1P in mammalian cells 
 
The observation that expression of SphK1, but not SphK2, decreases ceramide levels 
and increases dihydrosphingosine levels (3) suggests that S1P produced by SphK1 may 
negatively regulate one or more of the six (dihydro)ceramide synthases (CerS), leading to 
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accumulation of its substrate, dihydrosphingosine. Subsequently, using lysates from cells 
over-expressing individual CerSs, S1P was shown to be a non-competitive in vitro 
inhibitor of CerS2, but not of other CerSs (88). In silico analysis found two domains in 
CerS2 with predicted homology to S1PRs, and mutation of one arginine to alanine in each 
of these two domains removed S1P inhibition without altering CerS activity (88). The 
authors concluded that S1P directly binds to, and inhibits, CerS2. However, it is also 
possible that S1P acts through intermediate proteins in cell lysates to inhibit CerS2. 
Moreover, CerS2 does not use C16 or C18 acyl CoAs as substrates, yet it is C16 and C18 
ceramides that are most affected by expression of SphK1 (3). Additionally, S1P produced 
by SphK1 reverses CerS1-induced chemosensitivity, suggesting that S1P directly affects 
CerS2 (81). Finally, it is not yet clear whether inhibition of CerS2 by S1P is a signal-
mediated affect or whether it is simply product feedback inhibition. Further work is needed 
to confirm that S1P binds to and inhibits CerS2. 
As mentioned previously, autocrine and/or paracrine transactivation of S1PRs is 
typically accompanied by translocation of SphK1 to the plasma membrane. However, both 
SphK1 and SphK2 have been shown to translocate to other cellular compartments, 
suggesting that S1P is produced locally in these compartments to act on specific 
intracellular targets. For example, SphK1 is targeted to internal membranes through 
interaction with RPK118 (64) and Acy1 (66). SphK1 is targeted to nascent phagosomes, 
where it promotes maturation into mature phagolysosomes (112). SphK1 has also been 
shown to translocate to the nuclear envelope during S-phase (113), and this translocation 
may play a role in the ability of SphK1 overexpression to promote the G1/S transition 
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(114). Conversely, SphK2 has been shown to be in the nucleoplasm in certain cells, where 
it acts to arrest cells in G1 (71,80). Moreover, SphK2 has a nuclear export signal sequence 
that is activated by phorbol ester-induced phosphorylation, likely through protein kinase D 
(115). Whether the nuclear export serves to promote SphK2/S1P signaling in the cytosol or 
to block SphK2/S1P signaling in the nucleus is unclear. In some cells, SphK2 has been 
shown to translocate to the ER under stress conditions and promote apoptosis (3). Indeed, 
targeting SphK1 to the ER induced apoptosis (75), suggesting that S1P produced at the ER 
has specific targets. 
A direct target for S1P in the ER has not conclusively been identified, although strong 
evidence indicates that S1P can activate thapsigargin-sensitive calcium channels, likely in 
the ER. S1P induced inositol trisphosphate receptor-independent release of calcium from 
permeablized cells (116) and from cell fractions rich in rough, but not smooth, ER (117). 
Consistent with these results, cells overexpressing SphK2, which localizes in part to the 
ER, were also shown to have elevated intracellular calcium (3). Conversely, fetal liver 
derived-mast cells from SphK2
-/-
 mice have a defect in calcium mobilization in response to 
IgE receptor crosslinking, and this defect cannot be restored with exogenous S1P (96), 
again suggesting an internal S1P target. Exogenous S1P increases calcium in HEK293 
cells, a response that can be inhibited with pertussis toxin. However, microinjection of S1P 
increases calcium bypassing the pertussis toxin block, again supporting a role for 
intracellular S1P in calcium release (118). Similarly, caged S1P can elicit calcium 
mobilization in cells that do not respond to exogenous S1P (119). Likewise, UTP 
stimulates calcium mobilization in a SphK-dependent manner, but this effect is not 
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mimicked by exogenous S1P (120). Finally, exogenous S1P itself can stimulate SphK, and 
SphK inhibitors reduced calcium release induced by S1P (121). Intracellular calcium 
release by S1P may be an evolutionarily ancient pathway, as it has been shown that S1P 
can increase calcium in yeast (104). In sum, these results strongly suggest that S1P is a 
second messenger that can activate calcium channels. 
Finally, there are other effects of S1P that cannot be explained by activation of the 
known S1PRs. For example, overexpression of SphK1 promotes survival of endothelial 
cells in part through PECAM-1 expression and activation of Akt, but exogenous S1P does 
not reproduce this effect (122). Dihydro-S1P and S1P bind and activate S1PRs with similar 
affinities, but dihydro-S1P cannot recapitulate all of the effects of S1P (123-126). For 
example, S1P but not dihydro-S1P, protects male germ cells from apoptosis, an effect that 
was linked to inhibition of NF-κB and activation of Akt (126). A similar protection pattern 
was observed for HL-60 and PC-12 cells (123). Conversely, S1P-phosphonate, which does 
not bind to S1PRs, also protects these cells from apoptosis (123), suggesting an 
intracellular action. Other studies using embryonic fibroblasts from S1PR knockout mice 
ruled out S1PR involvement, demonstrating that SphK1 overexpression stimulated growth 
and survival in wild type and in S1PR negative cells (127). In the APC
min/+ 
model of 
intestinal tumorigenesis, it was shown that SphK1
-/-
 mice, but not S1P1
-/+
, S1P2
-/-
, or S1P3
-
/-
 mice, had reduced tumor progression and size (128), suggesting an intracellular role for 
S1P. Moreover, SphK1 null mice had elevated levels of sphingosine but not S1P, so it is 
possible that reduced tumor progression and size was due to inhibitory effects of 
sphingosine rather than to the absence of S1P stimulation. S1PR knockouts were similarly 
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used to demonstrate that SphK2-induced apoptosis was S1PR independent (75). Consistent 
with a role for SphK2 in apoptosis, the FTY720 analog AAL(R), which is phosphorylated 
by SphK2 but only poorly by SphK1, induces apoptosis in Jurkat cells and primary 
splenocytes (129). The authors showed that AAL(R) had to be phosphorylated to affect 
cells as the non-phosphorylated AAL(R) isomer did not induce apoptosis in cells from 
SphK2
-/-
 mice. However, exogenous addition of phosphorylated AAL(R) was unable to 
induce apoptosis, suggesting both that phospho-AAL(R) must be generated at or near its 
site of action and that S1PRs are not involved in SphK2-induced apoptosis.  
Intracellular S1P has also been linked to regulation of inflammatory responses. CD4+ 
T cells from SphK2 knockout mice displayed a hyperactivated phenotype, increased 
proliferation, and enhanced secretion of cytokines and STAT5 activation in response to IL-
2 (130). This phenotype was physiologically relevant, as T cells from SphK2
-/-
 mice 
induced a much more rapid response than T cells from wild type littermates in an adoptive 
transfer model of inflammatory bowel disease. The hyperresponsiveness to IL-2 could not 
be reversed with exogenous S1P, indicating that internal S1P normally suppresses IL-2-
induced inflammatory responses. Interestingly, activation of the T cell receptor in Th1 and 
Th2 cells leads to increased expression of SphK1, but not SphK2, and SphK1 negatively 
regulates chemokine expression, though the authors did not examine whether exogenous 
S1P reproduced chemokine suppression (131). Similarly, it has been shown that in primary 
umbilical vein endothelial cells, the pro-inflammatory cytokine TNFα greatly increased 
expression of the S1P phosphatase SPP2 (132). Induction of SPP2 was required for the 
TNFα-induced production of IL-1β and IL-8. SPP2 is an integral membrane protein of the 
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ER, and its requirement for induction of inflammatory responses suggests that it acts at the 
ER to remove an inhibitory S1P signal. Moreover, downregulation of SPP1 demonstrated 
that it played no role in TNFα-induced cytokine secretion. As SPP1 is also an ER resident 
protein, these results suggest a role for S1P at a specific subcompartment of the ER. 
Moreover, parallel findings have been reported in yeast, where the S1P-specific 
phosphatases, YSR2 and YSR3, are both localized to the ER and have overlapping but 
distinct functions (6). 
Many studies have utilized SphK inhibitors to implicate S1P in various signaling 
pathways, but none have reported detection of S1P release (e.g. (133,134)), leading to the 
conclusion that S1P was acting intracellularly in these systems. Still, care should be used 
in interpreting these results as S1P release may have been below the limits of detection. 
Moreover, exogenous S1P can activate all surface S1PRs, resulting in net opposing effects. 
It is also possible that signaling events localize secretion of S1P to regions of the plasma 
membrane where specific receptors to be activated are localized. Thus, lack of detectable 
S1P secretion does not definitively show that S1PRs are not involved in a particular 
signaling pathway. 
Furthermore, studies in endothelial cells using the sphingosine kinase inhibitor SKI 
demonstrated that endogenously generated S1P functions as a positive modulator of 
calcium entry via store operated channels (SOC), whereas exogenously administered S1P 
initiated calcium release from the ER similar to histamine and decreased endothelial cell 
permeability (135). These results suggest that the production of intracellular S1P, and not 
   
 34 
the secretion of S1P to act on other immunoregulatory cells, is the primary determinant of 
the inflammatory response.  
Recently, a new study demonstrated that the vascular permeability inhibitor Ang-1 
stimulated SphK1 and led to increases in intracellular S1P and decreases in vascular 
permeability. This function remained undisturbed even when expression of S1P1-3 were 
downregulated (136). Exogenous S1P also decreased vascular permeability, but not in cells 
where S1PRs were downregulated (136). These results suggest that Ang-1/SphK1 actions 
on vascular permeability are mediated via an intracellular mechanism. 
 
1.15 Hypothesis and specific aims of the current study 
 
It is now clear that the bioactive lipid mediator S1P exerts effects both intracellularly 
and extracellularly (Figure C). In addition, it is clear that SphK1 and SphK2 are not only 
distributed differently throughout tissues and within cells, but that S1P produced by these 
kinases have different, sometimes opposite, downstream effects. How can one simple 
molecule like S1P have such a wide range of effects? It seems that in the case of S1P, the 
location of its production may be the major determinant of the resulting phenotype. The 
key to unlocking this riddle will be the inevitable discovery of intracellular S1P binding 
partners. Extensive studies of proteins in the nucleus, particularly those involved in the 
transcriptional machinery and the regulation of the cell cycle, are clearly indicated to 
elucidate the mechanism by which S1P is exerting its effects inside the cell. Additionally, 
the consequences of activation or inhibition SphK1 vs. SphK2 must be studied with more 
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scrutiny, as it is apparent that despite catalyzing the same reaction, they have different 
functions. In addition, because the intracellular actions of S1P involve apoptosis, cell 
growth, vascular permeability, and possibly many more functions related to cancer and 
other diseases, a full understanding of the intracellular actions of S1P will be needed to 
best design clinical therapies targeting SphKs and S1P production as well as S1PRs.  
Despite all of the evidence for intracellular actions of S1P, a bona fide intracellular 
target has yet to be identified. The overarching hypothesis of my dissertation research is 
that S1P interacts with specific intracellular targets that mediate its intracellular and/or 
intranuclear actions. Therefore, the focus of this work is to identify bona fide S1P target(s) 
and to characterize the mechanism by which intracellular S1P exerts its actions. 
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Figure C: S1P exerts both intracellular and extracellular effects. A variety of agonists 
can activate SphKs to produce S1P inside the cell, which can then transactivate S1PRs 
through inside-out signaling. In addition, formation of S1P by SphK1 (cytosolic) and 
SphK2 (both cytosolic and nuclear) can exert a variety of intracellular effects independent 
of S1PR activation. Pase= S1P phosphatase.  
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CHAPTER 2: Materials and Methods 
 
 
Reagents 
S1P, LPA, and Sph were obtained from BIOMOL (Plymoth Meeting, PA). Fetal bovine 
serum was obtained from Atlanta Biologicals (Atlanta, GA). Media (IMEM and DMEM), 
charcoal-stripped fetal bovine serum, TRIZol, HEPES, trypsin, sterile PBS, 
oligofectamine, lipofectamine, and pre-cast polyacrylamide gels were obtained from 
Invitrogen (Carlsbad, CA). Estradiol was obtained from Sigma-Aldrich (St. Louis, MO).  
S1P, LPA, or control lipid conjugated beads were obtained from Echelon Biosciences (Salt 
Lake City, UT). Primary antibodies were obtained as follows: PHB1: Neomarkers 
(Fremont, CA); PHB2: Millipore (Billirica, MA); β-tubulin, COXIV, CI, CII, CIII, CIV, 
HDAC1, HDAC2, Lamin A/C, OPA-1: Cell Signaling Technology (Beverly, MA); 
estrogen receptor alpha, V5: Santa Cruz (Santa Cruz, CA); SphK2: R. Proia, NIH. 
Secondary antibodies were obtained from Jackson ImmunoResearch (West Grove, PA). 
Primer probes for qPCR were obtained from Applied Biosystems (Foster City, CA). 
siRNA was obtained from Dharmacon (Fremont, CA). Protein A/G beads for 
immunoprecipitation were obtained from Santa Cruz (Santa Cruz, CA).  
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Cell culture and transfection 
MCF7 cells were cultured in phenol red-free IMEM supplemented with 0.25% glucose and 
10% FBS. In experiments where estradiol was added, cells were switched to 5% charcoal 
stripped FBS for 72 hours prior to experiment. HeLa cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% FBS and transfected with 
vector, SphK2, catalytically inactive SphK2
G212E
 , PHB1, PHB2, and ERE-Luc using 
FuGENE (Roche) according to the manufacturers protocol. SphK2, PHB2, and SphK1 
were downregulated by transfection with ON-TARGETplus SMARTpool (Dharmacon) 
against SphK1, SphK2, or PHB2 using Oligofectamine (Invitrogen) in OptiMEM 
(Invitrogen).  
 
Preparation of nuclear extracts/non-nuclear fractions 
A 10cm3 plate of ~80% confluent cells was washed with cold PBS, scraped in 1ml cold 
pbs, spun down, and re-suspended in 200µl buffer containing 10 mM HEPES (pH 7.8), 
10mM KCl, 0.1mM EDTA, 1mM Na3VO4, 1mM DTT, 1:500 protease inhibitors (Sigma) 
and 0.2mM PMSF, and incubated on ice for 15 min. NP-40 was added (0.75%) and cells 
were vortexed for 10 sec. Nuclei and NNF (Sup) were separated by centrifugation at 3000 
rpm for 3 min at 4°C. Nuclei (pellet) were re-suspended in 50µl buffer containing 20mM 
HEPES (pH 7.8), 0.4M NaCl, 1mM EDTA, 1mM Na3VO4, 1mM DTT and 1:500 protease 
inhibitors and incubated on ice for 15 min. Nuclear extracts were cleared by centrifugation 
at 14,000 x g for 5 min at 4°C. In experiments where whole tissue was used, a nuclear 
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purification kit (NUPER, Pierce, Rockford IL) was employed according to the 
manufacturer’s instructions. 
 
Synthesis of [
32
P]S1P 
In a glass tube, the following mixture was prepared: 10μg protein from HeLa cell extracts 
overexpressing SphK1, 1 ml SphK buffer (20mM Tris pH 7.4, 1mM EDTA, 0.5mM DOP, 
15mM NaF, 1mM β-mercaptoethanol, 1mM Na3VO4, 40mM β-glycerophosphate, 10% 
glycerol, 200mM KCl, protease inhibitor cocktail (Roche) 1:500), 65 μl 1mM sphingosine 
in 5% Triton X-100, 12 μl 1M MgCl2, 30 μl [γ-
32
P]ATP (10mCi/ml). The mixture was 
vortexed and incubated at 37°C for 60 minutes. The reaction was stopped by adding 1.6ml 
CHCl3/MeOH/HCl (100/200/1 vol/vol), 1ml 2M KCl, and 1ml CHCl3.  The mixture was 
vortexed and centrifuged at 8000 rpm for 5 minutes to separate phases. The upper aqueous 
phase was aspirated and discarded. The lower organic phase was mixed with 2ml MeOH, 
1ml CHCl3, 2ml 2M KCl, and 100μl NH4OH. This mixture was vortexed and centrifuged 
at 8000rpm for 5 minutes to separate phases. The upper aqueous phase was transferred into 
a clean tube and 3ml CHCl3 + 200μl HCl was added. The mixture was vortexed and 
centrifuged at 8000rpm for 5 minutes to separate phases. The upper aqueous phase was 
aspirated and discarded. The lower organic phase containing the [
32
P]S1P was retained, 
radioactivity determined, and 10μl was spotted on a silica gel G60 plate and developed in 
CHCl3/methanol/acetone/acetic acid/H2O (10/4/3/2/1). The plate was exposed to a 
phosphoimager screen to confirm the presence of [
32
P]S1P (migrating spot).  
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Native Gel S1P-Protein binding assay 
Nuclear or non-nuclear fractions were incubated with 10μl [32P]S1P for 30 minutes at 
room temperature. The mixture was mixes 1:1 with gel shift buffer (HEPES pH 7.8 50mM, 
KCl 250mM, EDTA 5mM, MgCl2 25mM, glycerol 50%) and loaded onto a 5% TBE non-
denaturing polyacrylamide gel. After running, the gel was dried using a gel dryer and 
exposed to a phosphoimager screen (Molecular Dynamics). 
 
SyproRuby staining 
Gels were fixed (10% methanol, 7% acetic acid, 30ml total) for 1 hour and stained with 
30ml SyproRuby (Invitrogen) at room temperature overnight. Gels were then washed 2 
times in wash buffer (30ml, 10% methanol, 7% acetic acid) for 30 minutes and exposed to 
UV light or analyzed on a phosphorimager to visualize protein bands. 
 
Lipid Bead Pulldown 
Control, S1P, or LPA coated agarose beads (Echelon Biosciences) equilibrated with 
binding buffer containing 10mM HEPES (pH 7.8), 150mM NaCl, and 0.5% NP-40 were 
mixed with extracts (10µg protein/1µl beads) diluted in binding buffer and rocked 
overnight at 4°C. Beads were washed 4 times with binding buffer (10µl buffer/1µl beads) 
and collected by centrifugation at 1000 rpm. After removing the supernatant, the beads 
were boiled in SDS-PAGE sample buffer and bound proteins analyzed by immunoblotting. 
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[
32
P]S1P Binding Assay 
A 10cm3 plate of 80% confluent MCF7 cells was washed in cold PBS, scraped in 1ml cold 
PBS, spun down, and lysed in 200µl immunoprecipitation buffer (IP buffer) (50mM Tris, 
100mM NaCl, 0.5% NP40, 50mM NaF, 1mM DTT, 1mM PMSF, PIC 1:500), cell debris 
was cleared by centrifugation, and protein concentration was determined using a 
colorimetric assay. Cell lysates were then incubated with 10µl [
32
P]S1P for 2 hours at 4°C 
with gentle agitation to facilitate S1P-protein binding. 50µl Protein A/G agarose beads 
(Santa Cruz) were then added and the lysates were agitated for an additional 2 hours to pre-
clear non-specific proteins. The beads were then spun down and the supernatant was 
divided equally into 3 Eppendorf tubes. Primary antibodies against PHB1, PHB2 or IgG 
were then added at a concentration of 2μg/mg lysate and allowed to rock overnight at 4°C. 
The following day, 50µl Protein A/G beads were added to each tube and rocked at 4°C for 
2 hours. Beads were then collected via centrifugation, washed 4 times in 500µl IP buffer, 
and then boiled in western sample buffer. Equal volumes from each sample were then 
counted in a scintillation counter and total radioactivity was determined from each IP 
experiment.   
 
Immunoblotting 
Cells were scraped in buffer containing 50mM Tris, 100mM NaCl, 0.5% NP40, 50mM 
NaF, 1mM DTT, 1mM PMSF, and protease inhibitor cocktail (PIC) diluted at 1:500 and 
incubated for 1 hour on ice with intermittent vortexing. Cell debris was spun down at 
14,000 x g for 2 minutes and supernatants were quantitated for protein content (BioRad). 
   
 42 
Equal amounts of proteins were separated by SDS-PAGE, transblotted to nitrocellulose, 
blocked with 5% non-fat dry milk in TBS containing 0.1% Tween-20 (TBST), and 
incubated with primary antibodies as indicated in figure legends. Primary antibodies were 
diluted in 5% non-fat dry milk in PBST at concentrations ranging from 1:500-1:2500. 
Immunopositive bands were visualized by enhanced chemiluminescence using secondary 
antibodies conjugated with horseradish peroxidase and Super-Signal West Pico 
chemiluminescent substrate (Pierce).  
 
Lipid-Protein overlay 
96-well polystyrene plates were washed once with butanol, once with ethanol and dried. 
Indicated amounts of lipids were suspended in ethanol and an equal volume of water was 
added. 100μl of this mixture was added to each well and was incubated for 90 minutes at 
37°C. The mixture was aspirated and washed 3 times with water. 100μl of blocking 
solution (0.1%BSA, 0.1% Tween-20) was then added to each well and incubated for 60 
minutes. Protein extracts were then added diluted in blocking solution and incubated for 90 
minutes at room temperature. The mixtures were aspirated and each well was washed 4 
times with PBST. Specific primary antibodies were then added and rocked at 4°C 
overnight. The following day the mixtures were aspirated, wells were washed 4 times with 
PBST, and secondary antibodies were added and incubated at room temperature for 1 hour. 
The wells were then washed 6X with PBST and 100μl of substrate solution was added, 
followed by 50μl sulfuric acid to stop the reaction. As negative controls, a completely 
blank well and a well that received only secondary antibody were included. 
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Luciferase Assay 
All cells were switched to 5% charcoal stripped FBS containing media 72 hours prior to 
transfection. For overexpression studies, HeLa cells were transfected with a combination 
of ERα and GpGL3-2XERE-PS2-Luc/TK-Renilla and increasing concentrations of PHB2, 
SphK2, SphK2
G212E
 (50ng/100ng/200ng/400ng) for 24 hours. For siRNA assays, MCF7 
cells were transfected with 50nM SmartPool siRNAs (Dharmacon) directed toward SphK1, 
SphK2, or scrambled control siRNA for 24 hours, then transfected with GpGL3-2XERE-
PS2-Luc/TK-Renilla for 24 hours. Cells were treated with 100nM E2 for 6 hours. Lysates 
were prepared using passive lysis buffer (Promega) and relative luciferase activity was 
measured using a dual-luciferase assay kit (Promega) in a tube luminometer. Values are 
expressed as a ratio of luciferase activity/renilla activity. 
 
Reverse Transcriptase-PCR 
Cells in a 6 well plate (~80% concluent) were washed in cold PBS and 1ml of TRIzol was 
added and allowed to incubate for 5 minutes. TRIzol was transferred into a 1.5ml tube and 
200µl CHCl3 was added and the tube was vigourously shaken for 15 seconds. After a 5 
minute incubation, tubes were spun to separate phases at 12,000 x g for 15 minutes. 400µl 
of the supernatant was then transferred into a clean tube and 500µl isopropanol was added 
and gently mixed. After a 5 minute incubation tubes were spun at 12,000 x g for 15 
minutes. Supernatnts were completely removed and the pellet was resuspended in 1ml 
fresh 70% ethanol. This pellet was then spun down at 7,500 x g for 5 minutes, supernatant 
removed, and then resuspended in 20µl H2O. Total RNA was isolated with
 
TRIzol reagent 
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(Invitrogen) and was reverse transcribed with
 
Superscript II (Invitrogen). Real-time PCR 
was performed with
 
pre-mixed primer probe sets obtained from Applied Biosystems
 
(Foster City, CA) using an ABI. 
 
Lipid extraction from cell culture 
Lipids were extracted from cells as previously described (137). Cells were washed twice 
with PBS, with the dishes tilted to aid in the removal of as much of the liquid as possible, 
then the cells were scraped from the dish in the residual PBS (typically < 0.2 ml) using 
Nalgene cell scrapers (Rochester, NY) and transferred into 13 x 100 mm borosilicate tubes 
with a Teflon-lined cap After adding 0.5 ml of CH3OH and 0.25 ml of CHCl3, the internal 
standard cocktail (500 pmol of each species dissolved in a final total volume of 10 µl of 
ethanol) was added and the contents were dispersed using a Branson 1510 ultra sonicator 
(Sigma) at room temperature for 30 seconds. This single phase mixture was incubated at 
48°C overnight in a heating block, which affords optimal extraction of sphingolipids due to 
their high phase transition temperatures. After cooling, 75 μl of 1 M KOH in CH3OH was 
added and, after brief sonication, incubated in a shaking water bath for 2 hours at 37°C to 
cleave potentially interfering glycerolipids. After cooling to room temperature, 
approximately 6 μl of glacial acetic acid was added to bring the extract to neutral pH, and a 
0.4 ml aliquot was transferred to a new test tube to serve as the “Single phase extract” 
(which was centrifuged to remove the insoluble residue, the supernatant collected, the 
residue re-extracted with 1 ml of methanol:CHCl3, 1:2, v:v, centrifuged, and the 
supernatants combined). To the remainder of the original extract was added 1 ml of CHCl3 
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and 2 ml of H2O followed by gentle mixing then centrifugation using a table-top 
centrifuge, and the lower layer (the “organic phase extract”) was transferred to a new tube. 
The upper phase was extracted with an additional 1 ml of CHCl3, which was also added to 
the “organic phase extract.” The solvents were removed from the “single phase extract” 
and the “organic phase extract” using a Savant AES2000 Automatic Environmental Speed 
Vac. The dried residue was reconstituted in 0.3 ml of the appropriate mobile phase solvent 
for LC-MS/MS analysis, sonicated for 15 sec, then transferred to a microcentrifuge tube 
and centrifuged at 14,000 to 16,000 x g for several min (as needed) before transfer of the 
clear supernatant to the autoinjector vial for analysis. 
 
Mass spectrometric analysis of lipids 
Lipids were analyzed with ESI/MS/MS as previously described (137) with a Shimadzu 
LC-10 AD VP binary pump system coupled to a Perkin Elmer Series 200 autoinjector and 
a 4000 quadrupole linear-ion trap (QTrap) (Applied Biosystems, Foster City, CA) 
operating in a triple quadrupole mode. Units are expressed using the following formula: 
 
pmol of analyte of interest = Kanalyte x (Aanalyte / AIS) x pmol of added internal standard 
 
Electron Microscopy 
Mouse livers or hearts were minced into ~1mm
3
 pieces and fixed in 2% paraformaldehyde/ 
2% glutaraldehyde in 0.1M sodium cacodylate buffer. Samples were then rinsed in 0.1M 
cacodylate buffer for 10 minutes and then fixed in 1% osmium tetroxide in 0.1M 
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cacodylate buffer for 1 hour. Samples were then rinsed in 0.1M cacodylate buffer for 10 
minutes and then dehydrated in a graded ethanol series 50%, 70%, 80%, 95% for 5-10 
minutes each. Samples were then dehydrated in 100% ethanol 3 times for 15 minutes each, 
followed by propylene oxide incubation 3 times for 15 minutes each. Samples were then 
infiltrated with 50/50 mix of propylene oxide and PolyBed 812 resin mix overnight. The 
following day, samples were infiltrated with pure PolyBed 812 resin (Polysciences, Inc.)  
mix overnight. Samples were embedded in molds and placed in a 60˚C oven overnight. 
Sections were prepared on a Leica EM UC6i Ultramicrotome (Leica Microsystems). 
Sections (700-900A thick) were placed on grids, stained with 5% uranyl acetate and 
Reynold’s Lead Citrate, and images were taken on a JEOL JEM-1230 TEM  (JEOL USA, 
Inc.) with the Gatan Ultrascan 4000 digital camera (Gatan Inc, Pleasanton, CA). 
 
Liver Cellular Fractionation 
Whole cell lysates were prepared by douncing livers in lysis buffer (50mM Tris, 100mM 
NaCl, 0.5% NP40, 50mM NaF, 1mM DTT, 1mM PMSF, protease inhibitor cocktail 
1:500), incubating at 4°C for 2 hours, centrifuging cellular debris and collecting 
supernatants. Mitochondria were prepared (“percol method”) by douncing liver in sucrose 
buffer (250mM sucrose, 10mM HEPES, 1mM EDTA, PIC 1:500), centrifuging at 1000 x g 
for 10 minutes, collecting supernatant, centrifuging again at 1000 x g for 10 minutes, and 
running the supernatant on a sucrose/percol gradient. Cytosol was prepared by centrifuging 
the first supernatant from the mitochondrial preparation at 100,000 x g for 1 hour. 
Antibodies directed at cytosolic (β-tubulin), nuclear (lamin A/C), and mitochondrial (OPA-
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1, COX4) markers were used to confirm fraction purity, and antibodies against PHB1, 
PHB2, and SphK2 were used to determine their subcellular localization. 
 
 
Preparation of heart mitochondria 
Mitochondria from mouse hearts were prepared as previously described (“Hoppel method” 
(138)). Briefly, mouse hearts were harvested while still beating and immediately placed in 
cold buffer containing 100mM KCl, 50mM 3-(N-morpholino)propanesulfonic acid 
(MOPS), 1mM EGTA, 5mM MgSO4, 1mM ATP and 0.2 % bovine serum albumin (BSA), 
pH 7.4 at 4°C. Cardiac tissue was homogenized with a glass tissue grinder and the 
homogenate was centrifuged at 500 x g for 10 minutes. The supernatant was then 
centrifuged at 3000 x g for 10 minutes to sediment the mixed population of mitochondria. 
After one washing step, the pellet was suspended in 100mM KCl, 50mM MOPS, and 
0.5mM EGTA.  
 
Measurement of Oxidative Phosphorylation 
Oxygen consumption in mitochondria was measured using a Clark-type oxygen electrode 
at 30°C. Mitochondria were incubated in a solution containing 80mM KCl, 50mM MOPS, 
1mM EGTA, 5mM KH2PO4, and 1mg/ml bovine serum albumin, at pH 7.4. 
Glutamate/malate (complex I substrate), succinate (complex II substrate), and TMPD-
ascorbate (complex IV substrate) were used as electron donors to specific sites in the 
electron transport chain. State 3 (ADP-stimulated), state 4 (ADP-limited) respiration and 
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respiratory control ratio (RCR) were measured. These experiments were carried out in 
collaboration with Melanie Paillard and Dr. Edward Lesnefsky. 
 
 
Measurement of Reactive Oxygen Species  
The rate of H2O2 production in mitochondria was determined using the oxidation of the 
fluorogenic indicator amplex red in the presence of horseradish peroxidase. The 
concentrations of horseradish peroxidase and amplex red in the incubation were 0.1 unit/ml 
and 50µM , respectively. Fluorescence was recorded in a microplate reader (1420 Victor2, 
PerkinElmer Life Sciences) with 530nm excitation and 590nm emission wavelengths. 
Standard curves obtained by adding known amounts of H2O2 to assay medium in the 
presence of the reactants (amplex red and horseradish peroxidase) were linear up to 2µM. 
Background fluorescence was measured in the absence of mitochondria and presented as 
fluorescence minus background (pmol/mg of protein/30 min). In a typical experiment, 
mitochondria were incubated at 0.1mg of protein/ml at 30°C. H2O2 production was 
initiated in mitochondria using glutamate (10mM ), pyruvate (2.5mM )/malate (2mM ), or 
succinate (5mM ) as substrates. Rotenone (2.4µM ) and antimycin A (10µM ) were added 
into incubation medium to inhibit the activities of complex I and complex III, respectively. 
These experiments were carried out in collaboration with Melanie Paillard and Dr. Edward 
Lesnefsky. 
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Calcium Retention Capacity (CRC) 
Calcium retention capacity (CRC) is defined as the amount of Ca
2+
 required to trigger a 
massive Ca
2+
 release by isolated mitochondria. It is used as an indicator of the resistance of 
the mPTP to opening following matrix Ca
2+
 accumulation, and expressed as nmol 
CaCl2/mg mitochondrial protein. Extramitochondrial Ca
2+
 concentration is recorded with 
0.5μM Calcium Green-5N with excitation and emission wavelengths set at 500 and 530nm, 
respectively, on a LS55 fluorimeter (Perkin Elmer). Isolated mitochondria (250μg proteins) 
were suspended in 2ml of buffer (150mM sucrose, 50mM KCl, 2mM KH2PO4, 5mM 
succinic acid in 20mM Tris/HCl, pH 7.4). After 60 seconds of pre-incubation, 10nmol 
CaCl2 pulses were performed every 60 seconds. Following sufficient calcium loading, 
extra-mitochondrial calcium concentration abruptly increases indicating a massive release 
of calcium by mitochondria due to mPTP opening. These experiments were carried out in 
collaboration with Melanie Paillard and Dr. Edward Lesnefsky. 
  
   
 50 
CHAPTER 3: Results 
 
 
3.1 PHB2 binds S1P in the nucleus 
 
Given the accumulated evidence for an intracellular function of S1P, and the lack 
of known bona fide intracellular targets, we sought to identify proteins within the cell that 
would specifically interact with S1P. Because SphK2 was localized in the nucleus of 
MCF7 breast cancer cells (82), we chose to examine proteins within the nucleus of these 
cells to determine if any of them would bind to S1P. In this regard, we prepared [
32
P] 
labeled S1P and incubated it with nuclear extracts or cytosolic fractions (non-nuclear 
fractions) prepared from MCF7 cells to facilitate S1P-protein interaction. This mixture was 
then run on a non-denaturing gel, which was then dried and exposed to a phosphorimaging 
screen overnight, and visualized on a phosphoimager the following day (Figure 1). Bovine 
serum albumin (BSA), a known S1P carrier, was used as a positive control. BSA clearly 
bound to [
32
P]S1P
 
in this experiment, and this binding was abolished by pre-incubation 
with high concentrations of non-labeled S1P (Figure 1A). Both nuclear fractions and non-
nuclear fractions produced a band containing [
32
P]S1P
 
with similar migration and distinct 
mobility (Figure 1B). This band was confirmed to be protein(s) that bound S1P by pre-
treating nuclear extracts with trypsin at 37°C to digest any proteins, which abolished the 
band (Figure 1C). The purity of our nuclear extraction was confirmed with western 
blotting for Lamin A/C, a known nuclear marker (Figure 1D). Despite consistently 
detecting the same band of radioactivity with reproducible mobility, we were unsuccessful 
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Figure 1: S1P binds to proteins from MCF7 cells. A: BSA binds S1P. [
32
P]S1P (6 x 10
6
 
cpm/pmol was incubated for 15 min at 25 ˚C with increasing concentrations of BSA or 
with BSA in the presence of 10μM unlabeled S1P. Samples were run on a 5%TBE non-
denaturing gel and visualized on a phospho-imager. B: S1P binds to a protein in the 
nucleus and non-nuclear fraction of MCF7 cells. [
32
P]  S1P was incubated with BSA, 10 
µg nuclear extract (NE), or 10 µg non-nuclear fraction (NNF) at room temperature. C. 
10ug nuclear extract was incubated with or without 0.2 μg  trypsin for 30 minutes at 37°C. 
D. Western blot for the nuclear marker lamin A/C was performed to confirm purity of 
nuclear fraction. E. Silver stain of S1P binding protein(s) and BSA in a non-denaturing gel. 
S1
32
BP:  [
32
P]S1P binding protein. 
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in our attempts to excise this band and identify the protein(s) present with mass 
spectrometry.  
To overcome this problem, we employed S1P-conjugated agarose beads in a pull-
down experiment from MCF7 nuclear extracts. Nuclear extracts were incubated with S1P-
coated beads or with control beads overnight. The following day the beads were washed 
extensively and then boiled in SDS-PAGE sample buffer, and the supernatants were run on 
a SDS-PAGE gel. The gel was then stained with SyproRuby protein stain and bands were 
visualized with a phosphoimager (Figure 2A). An additional sample was prepared 
containing S1P coated beads but with no nuclear extract as a control for any proteins 
contained within the S1P bead mixture itself. After repeating this experiment several times, 
we noticed a band consistently running between 30-40 kD in the S1P-coated bead lane that 
was absent in proteins from control beads. This band was excised and sequenced via 
MALDI-TOF mass spectrometry (Center for Proteomics, UMDNJ, New Brunswick, NJ). 
The sequencing results indicated that the protein was prohibitin-2 (PHB2), a pleiotropic, 
evolutionarily conserved protein with a variety of cellular localizations and reported 
functions. We were confident in the sequencing results as 9 peptides, spanning the entire 
length of the protein, were identified (Figure 2B). 
To confirm the S1P-PHB2 interaction and demonstrate specificity, we employed 
several techniques. First, antibodies directed at PHB2 were used to analyze S1P bead  
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Figure 2: Identification of PHB2 as a S1P binding protein. A: MCF7 nuclear extracts 
were incubated with S1P or control beads. After extensive washing, the beads were boiled 
in western sample buffer and supernatants were separated by SDS-PAGE and stained with 
SyproRuby protein stain (Invitrogen). The indicated band was excised and MS/MS protein 
mass spectrometry analysis was performed. B: Table of sequences identified by mass 
spectrometry. Nine peptide sequences were obtained spanning 91% of human PHB2 amino 
acids. C. Entire amino acid sequence of PHB2. Bolded regions indicate identified peptide 
sequences. 
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pulldown fractions with western blotting (Figure 3). MCF7 nuclear extracts were prepared 
and incubated overnight with S1P beads, control beads, or lysophosphatidic acid (LPA) 
beads. We also blotted for PHB1 because it is closely related to PHB2 in structure and is 
known to physically interact with PHB2 (see Discussion). As can be seen in Figure 3A, 
S1P beads effectively pulled down PHB2, but control beads and LPA beads were unable to 
pull down PHB2. In addition, PHB1 was not pulled down by any beads, despite its 
presence in the nuclear extracts. In addition, pre-incubation of nuclear extracts with 
exogenous S1P prevented the S1P beads from pulling down PHB2 (Figure 3B). 
To further confirm the specificity of the PHB2-S1P interaction, we immobilized 
S1P and a variety of other lipids onto polystyrene plates and conducted lipid-protein 
overlay experiments (Figure 4). PHB2 bound to S1P fixed on polystyrene and the degree 
of binding increased with increasing S1P concentrations, while PHB1 failed to bind 
(Figure 4A). To further confirm this specificity, we immobilized LPA, Sphingosine (Sph), 
and phosphatidylcholine (PC) in addition to S1P onto polystyrene plates. In this 
experiment, PHB2 only bound to the S1P containing lanes (Figure 4B). Finally, in a 
separate experiment, both PHB1 and PHB2 were analyzed on wells containing S1P, LPA, 
or Sph, as well as the appropriate negative controls. Again, only PHB2 significantly bound 
to S1P (Figure 4C). This provided further evidence that the PHB2-S1P interaction was 
specific and not simply a result of “stickiness” of PHB2 or S1P. 
Our next approach to demonstrate S1P-PHB2 interaction was to synthesize 
[
32
P]S1P, incubate it with MCF7 cell lysates, and immunoprecipitate PHB2 and PHB1  
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Figure 3: PHB2 specifically binds S1P. A: Nuclear extracts (NE) from MCF-7 cells were 
incubated with control, LPA, or S1P affinity matrices, as indicated, washed extensively 
and bound proteins separated by SDS-PAGE and then analyzed by Western blotting with 
anti-PHB2 or anti-PHB1 antibodies. Input (1% of NE) is shown on the left. B: MCF7 
nuclear extracts were pre-incubated with vehicle or S1P (10 µM) for 2 hours followed by 
incubation with S1P beads. After extensive washing, S1P beads were boiled in western 
sample buffer and bound proteins were separated by SDS-PAGE and western blots with 
indicated antibodies were performed.  
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Figure 4: PHB2 binds to immobilized S1P. A: PHB2 binds to S1P in a S1P concentration 
dependent manner. Either no lipid or increasing concentrations of S1P (10, 100, 1000 
pmol) were immobilized on polystyrene plates. MCF7 nuclear extracts or nuclear 
extraction buffer alone was then added and allowed to bind to immobilized lipid. Bound 
proteins were then analyzed with the indicated antibodies and binding was quantitated 
using a colorimetric assay.  B. Either no lipid or 10 nmol of S1P, LPA, Sph, or PC were 
immobilized as described in A, incubated with MCF7 nuclear extracts, and probed with 
PHB2 specific primary antibodies. C. Either no lipid or 10 nmol S1P, LPA, or Sph were 
immobilized and incubated with MCF7 extracts as described in A and probed with the 
indicated antibodies. In “S1P-Ab” samples, the addition of primary antibody was omitted. 
The “Blank” sample is an empty well with the chemiluminescent substrate added to assess 
background. All data are means of quadruplicate experiments. *: p-value < 0.05. 
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with specific antibodies and quantitate bound S1P. After immunoprecipitation, the 
prohibitin-antibody complexes were collected with Protein A/G agarose beads and bound 
proteins were examined by western blotting and bound radioactivity (Figure 5A-B). We 
found that immunoprecipitating PHB1 would co-immunoprecipitate equal amounts of 
PHB2 and vice versa (Figure 5A). The co-immunoprecipitation of PHB1 and PHB2 was 
not surprising, as many other studies have confirmed PHB1-PHB2 interaction (see 
Discussion). [
32
P]S1P was effectively immunoprecipitated with PHB2 antibodies when 
compared to PHB1 or isotype matched IgG control antibodies, indicating that [
32
P]S1P was 
bound to PHB2 (Figure 5B). In an additional experiment, we immunoprecipitated PHB1 
and PHB2 and employed mass spectrometry to determine the amount of endogenous S1P 
that bound to PHB1 or PHB2. In this experiment we found that S1P was bound at 
significantly higher amounts to PHB2 than to PHB1 or IgG (Figure 5C). Interestingly, 
significantly more S1P was present in the PHB2 immunoprecipitates than in the PHB1 
immunoprecipitates, despite equal amounts of each protein being present in both fractions 
(Figure 5B and 5C). These results suggest that S1P binds to PHB2 only when PHB2 is not 
bound to PHB1. 
Because we saw a specific interaction between S1P and PHB2 in the nucleus, it 
was of interest to examine whether SphK2, the enzyme that likely produces S1P in the 
nucleus, was associated with PHB2. V5-tagged SphK2 was ectopically expressed in MCF7 
cells and nuclear extracts were prepared. Using agarose beads conjugated to anti-V5  
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Figure 5: S1P is bound to PHB2 in cells. A: PHB1 and PHB2 co-immunoprecipitate from 
MCF7 cells. PHB1 and PHB2 were immunoprecipitated from MCF7 cell lysates with the 
indicated antibodies, immunoprecipitants were washed extensively and boiled in western 
sample buffer, separated by SDS-PAGE, and immunoblotted with specific antibodies for 
PHB1 and PHB2.  B: PHB2 binds [
32
P]S1P. [
32
P]S1P (12652 cpm, 0.1 nM) was pre-
incubated with 200 μg of MCF7 cell lysate in the absence or presence unlabeled S1P (10 
µM) or sphingosine (Sph, 10 µM) for 30 minutes at room temperature. Cell lysates were 
then immunoprecipitated with the indicated antibodies, immunoprecipitants were washed 
extensively and boiled in western sample buffer, and radioactivity of the supernatants was 
determined by scintillation counting. C: PHB1 and PHB2 were immunoprecipitated from 
500 μg MCF7 cell lysates, immunoprecipitants were washed extensively, and endogenous 
levels of S1P bound were determined by LC-ESI-MS/MS. *: p-value < 0.05. 
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Figure 6: Ectopically expressed SphK2 interacts with PHB2 and HDAC1 in MCF7 
nuclei. Nuclear extracts from MCF-7 cells transfected with vector or V5-SphK2 were 
incubated with anti-V5 antibody coupled to agarose beads, bound proteins eluted with V5 
peptide, separated by SDS-PAGE, and then blotted with the indicated antibodies. Input = 
1.0% total protein used in pull down.  
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antibody, we immunoprecipitated SphK2 and used western blotting to determine whether 
PHB2 would co-immunoprecipitate with SphK2 (Figure 6). Indeed, PHB2 co-
immunoprecipitated with SphK2 in SphK2 transfected cells, but not in cells transfected 
with empty vector plasmid. In an unpublished study from our lab of which I am a co-
author, I have demonstrated that S1P specifically interacts with HDAC1 and HDAC2 in 
the nucleus of MCF7 cells (see Appendix A). In Figure 6, we examined whether histone 
deacetylase 1 (HDAC1) also co- immunoprecipitated with SphK2. Interestingly, HDAC1 
and PHB2 were also associated with SphK2 (Figure 6). This is consistent with a previous 
published report demonstrating that PHB2 and HDAC1 can physically interact (139). 
Taken together, these results suggest the possibility that SphK2, HDAC1, PHB2, and S1P 
may be part of a dynamic complex that regulates gene expression in the nucleus of cancer 
cells.  
 
3.2 S1P augments E2-mediated transcriptional repression in the nucleus 
 
Because both PHB2 and SphK2 are known to be localized in the nucleus of MCF7 
cells, we first decided to determine the function of S1P-PHB2 interaction in that cell type. 
Prohibitins have been demonstrated in several studies to interact with transcriptional 
elements, and PHB2 in particular has been demonstrated to repress estradiol-mediated 
transcriptional events by binding to estrogen receptor alpha (ERα) (140-149). To address 
the question of whether S1P production in the nucleus could augment or repress the effect 
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of PHB2 on estradiol mediated transcription, we utilized an ERE-luciferase promoter assay 
and examined the effects of transfections with PHB2, V5-SphK2, and V5-SphK2
G212E
, a 
catalytically inactive form of SphK2 that cannot make S1P (Figure 7A). Transfection with 
ERE-Luciferase and ERα plasmids followed by treatment with estradiol (E2) led to a 
robust luciferase expression when compared to ERE-luciferase only transfected cells, 
which showed no luciferase expression due to their lack of ERα (data not shown). Co-
expression of increasing amounts of PHB2 in ERα transfected cells suppressed ERE-
luciferase expression in a dose-dependent manner (Figure 7B), consistent with other 
published findings (147). Transfection with SphK2 also suppressed luciferase expression 
to a similar degree as PHB2 (Figure 7B). Interestingly, transfection with a catalytically 
inactive form of SphK2 failed to mimic the effects of wild-type SphK2. This result directly 
implicates S1P in the nucleus as the responsible factor for this transcriptional repression, as 
unpublished results from our lab (Hait et al) have clearly demonstrated that transfection 
with SphK2, but not SphK2
G212E
 or SphK1, dramatically increases intra-nuclear S1P 
levels. 
Because over-expressing SphK2 suppressed E2-mediated transcription and 
depletion of PHB2 has been shown to enhance it (150), we wanted to determine whether 
depletion of SphK2 in cells that endogenously express ERα would affect E2-mediated gene 
transcription. PHB2, SphK1, or SphK2 levels were depleted in MCF7 cells with small 
interfering RNA (siRNA) and then transfected with an ERE-Luciferase/Renilla dual 
luciferase assay kit. Luciferase activity was measured after treatment with E2 (Figure 8).  
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Figure 7: S1P and PHB2 suppress E2-mediated transcription. A: HeLa cells were 
plated on 24 well plates and transfected with 100ng of the following plasmids: pCDNA 3.1 
(Vector), pERα, pPHB2, pSphK2-V5, and pSphK2G212E-V5. Cells were lysed and proteins 
were separated by SDS-PAGE and immunoblotted with the indicated antibodies to confirm 
successful transfection. B: HeLa cells were co-transfected with the increasing 
concentrations (50ng, 100ng, 200ng, 400ng) of the indicated plasmids plus ERα + ERE-
Luciferase/Renilla reporter constructs. Cells were treated with 100nM E2 for 6 hours, cell 
lysates were prepared, and luciferase activity, normalized to Renilla expression, was 
determined by luminometry. Values are the means and SD from 6 separate experiments. *: 
p-value < 0.05. 
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Depletion of SphK2, but not SphK1, significantly augmented E2-mediated luciferase 
expression. This result is consistent with our unpublished data demonstrating that only 
siSphK2 decreases nuclear levels of S1P while siSphK1 only decreases cytosolic levels of 
S1P.  
To confirm the results obtained above, we used siRNA to knockdown the 
expression of SphK2 and PHB2 in MCF7 cells and then measured E2-mediated 
transcription of the endogenous E2 responsive genes pS2 and cathepsin D (Figure 9). 
Treatment with 100nM E2 for 18 hours was sufficient to induce transcription of both pS2 
and cathepsin D. In cells that were depleted of SphK2, the transcription of these genes was 
more robust, in agreement with our ERE-luciferase data. This suggests that nuclear S1P 
has a direct effect on E2-mediated transcription and is not an artifact of an over-expression 
system. Interestingly, and in contrast to a recently published study (150), siPHB2 had no 
effect on E2-mediated gene transcription. This may have been due to the fact that despite 
~90% reduction in PHB2 mRNA, the protein levels of PHB2 were only reduced by ~50% 
(data not shown), so the remaining PHB2 may have been sufficient to repress E2-mediated 
transcription in these samples.  
 
3.3 Mitochondrial S1P-PHB2 interaction and function 
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Figure 8: Depletion of SphK2 increases ERE-Luciferase expression. MCF7 cells were 
transfected with siControl, siSphK1, siSphK2, or left untransfected (no siRNA). After 24 
hours, cells were transfected with ERE-Luciferase/Renilla (Promega) for 24 hours. Cells 
were then treated with 100nM E2 for 6 hours and luciferase activity, normalized to Renilla 
activity, was measured by luminometry. Values are the means and SD from 3 separate 
experiments. 
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Figure 9: Depletion of SphK2 augments endogenous E2-mediated transcription. 
MCF7 cells were transfected with the indicated siRNAs for 72 hours, followed by 10nM 
E2 treatment overnight. RNA was isolated from cells and reverse transcribed to cDNA, 
and real time PCR was performed on the indicated genes. Values are normalized to 
GAPDH expression. Values represent means of 3 separate experiments. *: p-value < 0.05. 
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Because prohibitins are mainly localized in the mitochondria, we sought to 
determine what function, if any, the PHB2-S1P interaction played there. We first 
fractionated mouse livers from SphK2
-/-
 and SphK2
+/+
 mice into whole cell lysates, nuclear 
extracts, purified cytosol, and purified mitochondria (Figure 10), in order to determine the 
cellular localization of prohibitins and SphK2 in those cells. Antibodies against 
cytochrome c oxidase subunit IV (COX4) and OPA-1 were used as mitochondrial markers, 
antibodies against lamin A/C was used as a nuclear marker, and β-tubulin antibody was 
used as a cytosolic marker. As in previously published reports, we found both PHB1 and 
PHB2 to be enriched in the nuclear and mitochondrial fractions (Figure 10A). Using 
purified mitochondrial fractions from SphK2
-/-
 and SphK2
+/+
 mouse livers and mouse 
specific SphK2 polyclonal antibodies, we demonstrated that SphK2 is present in both the 
nuclear enriched fraction and in SphK2
+/+
 mitochondria purified by differential 
centrifugation (Figure 10B).  
We next sought to determine if PHB2 from purified mitochondria would bind to 
S1P-coated beads. Purified mouse liver mitochondria were incubated in S1P bead buffer 
supplemented with 2% CHAPS detergent to facilitate mitochondrial membrane disruption 
and then the S1P bead pulldown assay previously described in Figures 2 and 3 was 
performed. As we saw in MCF7 and HeLa cells, PHB2 from mouse mitochondria 
specifically bound to S1P coated beads, while PHB1 failed to bind (Figure 11). 
Interestingly, while SphK2
-/-
 mice did not have different expression levels of liver 
mitochondrial PHB2 or PHB1 from their wildtype counterparts (Figure 10A), more PHB2  
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Figure 10: PHB2 and SphK2 are present in mitochondria and nuclei. A. Cellular 
fractionation of mouse liver. Nuclei were prepared from liver homogenates of wild-type 
and SphK2 knockout mice using a NuPER nuclear purification kit. Mitochondria and 
cytosolic fractions were prepared by differential centrifugation. Purity of fractions was 
determined by western blotting with specific antibodies: anti-tubulin (cytosol), anti-lamin 
A/B (nuclei), and anti-OPA-1 and COXIV (mitochondria). Expression of PHB1 and PHB2 
was also determined with specific antibodies. B: Nuclear and mitochondrial fractions were  
analyzed for the presence of SphK2 with specific antibodies. Mitochondrial fractions were 
prepared using Percol purification (Percol) or via the Hoppel method (Hoppel).  
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Figure 11: Mitochondrial PHB2 binds S1P.. Mouse livers were harvested from 8 week 
old C57/B6 (WT) or SphK2
-/-
 mice and liver homogenates or mitochondrial fractions were 
prepared. Liver homogenates or mitochondrial fractions were diluted in S1P bead binding 
buffer and incubated with S1P coated beads. After extensive washing, the beads were 
boiled in western sample buffer. Western blot analysis on the S1P precipitated fractions 
was performed with antibodies for PHB1 and PHB2. 
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was consistently pulled down with S1P in the knockout cells. As was observed in other cell 
types, neither PHB1 nor PHB2 bound to control beads (data not shown). 
Next we determined the lipid composition of the tissue fractions from wildtype and 
SphK2
-/-
 mouse livers, hearts, and isolated cardiomyocytes. Mouse livers were fractionated 
into nuclear extracts, purified cytosol, and purified mitochondria and the lipid composition 
of each fraction was determined by ESI/MS/MS (Figure 12-13). Sphingosine levels were 
significantly elevated in SphK2
-/-
 nuclei, but remained relatively unchanged in cytosolic 
fractions or in mitochondria (Figure 12A). Dihydro-sphingosine levels were also elevated 
in nuclei from SphK2
-/-
 mouse livers but did not significantly change in other cell 
compartments (Figure 12B). S1P levels were markedly reduced in SphK2
-/-
 liver nuclear 
extracts when compared to wildtype but were unchanged in the cytosolic compartment 
(Figure 12C), consistent with our unpublished observations that depletion SphK2 reduces 
only nuclear S1P levels. Interestingly, S1P levels were markedly reduced in SphK2
-/-
 
mitochondria (Figure 12C), consistent with the observation that SphK2 is detectable by 
western blot in mitochondrial fractions (Figure 10B). Dihydro-S1P levels were also 
reduced in SphK2
-/-
 mouse liver nuclei, but remained unchanged in both cytosolic and 
mitochondrial fractions (Figure 12D). When ceramide levels were examined in the same 
fractions, we observed that the four abundantly detectable species of ceramide (C16:0, 
C22:0, C24:1, C24:0) were elevated in all cell compartments of SphK2
-/-
 mouse liver cells 
(Figure 13). Taken together, these results suggest that SphK2 is an important mediator of 
lipid homeostasis throughout mouse liver cells. 
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Figure 12: Mass spectrometric analysis of LCB lipids in mouse liver fractions. Mouse 
livers were harvested, separated into the indicated fractions, and analyzed with 
ESI/MS/MS. Each data point represents a sample collected from an individual mouse liver. 
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Figure 13: Mass spectrometric analysis of CSL lipids in mouse liver fractions. Mouse 
livers were harvested, separated into the indicated fractions, and analyzed with 
ESI/MS/MS. Each data point represents a sample collected from an individual mouse liver. 
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 To examine the role of SphK2 in lipid compartmentalization in other cell types, we 
isolated hearts from SphK2
-/-
 and wildtype mice and prepared whole cell lysates, nuclei, 
mitochondria, and intact cardiomyocytes and again determined their lipid composition by  
ESI/MS/MS (Figure 14). Sphingosine levels were significantly elevated in purified 
mitochondria from SphK2
-/-
 mouse hearts, but did not significantly change in other cell 
compartments or in intact cardiomyocytes (Figure 14A). Dihydro-sphingosine levels were 
slightly elevated in SphK2
-/-
 cardiomyocytes but were not significantly altered in other cell 
compartments. S1P and dihydro-S1P levels were significantly decreased in SphK2
-/-
 
cardiomyocytes and in all fractions of intact heart tissue (Figure 14C-D). Taken together 
with the results from Figures 12 and 13, these results again point to an important role of 
SphK2 in lipid homeostasis and suggest that this role may be differentially regulated in 
different tissues. 
Because we saw more PHB2 binding to S1P in SphK2
-/-
 mouse mitochondria 
(Figure 11), and because we saw significantly less S1P in SphK2
-/-
 liver mitochondria 
(Figure 12C), we hypothesized that this was due to endogenous S1P in the wildtype cells 
competing with the S1P bead binding site on PHB2. To confirm that S1P was bound to 
PHB2 in mouse mitochondria, we performed PHB2 immunoprecipitation experiments 
from both whole cells and liver mitochondrial fractions purified from both wildtype and 
SphK2
-/-
 mice. After the immunoprecipitation, S1P content of each IP fraction was 
determined by mass spectrometry. As we expected, more S1P was detected bound to PHB2 
in SphK2
+/+
 samples than the SphK2
-/-
 samples (Figure 15). While we saw a more dramatic 
decrease in S1P levels in the whole cell lysate fractions than mitochondria when  
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Figure 14: Mass spectrometric analysis of LCB lipids in mouse heart fractions and 
intact cardiomyocytes. Mouse livers were harvested, separated into the indicated 
fractions, and analyzed with ESI/MS/MS. Each data point represents a sample collected 
from an individual mouse liver.  
   
 74 
 
 
 
 
Figure 15: S1P is bound to endogenous mitochondrial PHB2. PHB2 was 
immunoprecipitated from SphK2 knockout or wildtype mouse liver homogenates. After 
extensive washing, the endogenous levels of S1P bound to PHB2 in the pelleted beads 
were determined by LC-ESI-MS/MS. 
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the mutant and wildtype were compared, this corresponds to the pattern of S1P bead 
binding shown in Figure 11. It also corresponds to our initial binding data in Figure 3B, 
where exogenous S1P ablated the beads’ ability to bind PHB2. Taken together, these 
results strongly suggest that S1P formed by SphK2 specifically interacts with PHB2 in the 
mitochondria. Because some S1P was still detected in the SphK2
-/-
 samples, it is possible 
that S1P from SphK1 may also bind to PHB2. Since we cannot rule out SphK1 
compensation in the SphK2
-/-
 mice, more studies will need to be done to confirm if S1P 
from both SphKs play a role in PHB2 binding and function. 
Because the PHB1/PHB2 complex has been shown to be a mitochondrial inner 
membrane chaperone that interacts with and protects newly synthesized components of the 
electron transport chain (151-155), we sought to determine if SphK2
-/-
 mice had any 
deficiencies in mitochondrial respiration. In collaboration with Melanie Paillard and Dr. E. 
Lesnefsky, oxygen consumption in intact heart mitochondria was measured in a Clark-type 
electrode. Using glutamate as a substrate to assess complex I function, we observed that 
state 3 respiratory rates (oxygen consumption in the presence of ADP) were lower in 
SphK2
-/- 
mice than their wildtype counterparts (Figure 16A). We observed the same 
decrease in oxygen consumption when succinate was used as a substrate (to assess 
complex II function) (Figure 16B) or when TMPD-ascorbate was used as a substrate (to 
assess complex IV function) (Figure 16C). The decrease in the oxidation rate of TMPD-
ascorbate, an electron donor at cytochrome c-cytochrome oxidase (complex IV), suggested 
a defect at complex IV. This defect in respiration was also observed in the presence of the  
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Figure 16: Depressed mitochondrial respiration in SphK2
-/-
 mice. Heart mitochondria 
were isolated wild type (WT) and SphK2
-/-
 mice. A: Oxygen consumption of complex I 
was assessed with glutamate/malate as a substrate. State 3 & state 4: oxygen consumption 
in the presence or absence of 0.2mM ADP, respectively. RCR: respiratory control rate. 
2mM ADP: rate of oxygen consumption in the presence of excess ADP. DNP: Rate of 
oxygen consumption in the presence of 2-4 dinitrophenol. B: Oxygen consumption of 
complex II was assessed with succinate as a substrate. State 3 & state 4: oxygen 
consumption in the presence or absence of 0.2mM ADP, respectively. RCR: respiratory 
control rate. 2mM ADP: rate of oxygen consumption in the presence of excess ADP. DNP: 
Rate of oxygen consumption in the presence of 2,4-dinitrophenol. C: Oxygen consumption 
of complex IV was assessed with TMPD-ascorbate as a substrate. TMPD: basal complex 
IV oxygen consumption. 2mM ADP: rate of complex IV oxygen consumption in the 
presence of excess ADP. Azide: rate of complex IV oxygen consumption in the presence 
of the complex IV inhibitor azide. T-A: 2mM ADP rate – azide rate (azide sensitive 
oxygen consumption). Values are means ± SE. n = 6/group. Units are nanoatoms O 
.
 min
-1
 
.
 
mg protein
-1
. 
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uncoupler 2,4-dinitrophenol, indicating that the respiratory defect exists in the electron 
transport chain itself and not at the level of the ATP-synthase (complex V).  
Because defects in the electron transport chain have been demonstrated to influence 
the amount of reactive oxygen species (ROS) produced in intact mitochondria (156), we 
sought to determine the state of ROS production in SphK2
-/-
 mouse heart mitochondria. 
Using glutamate as a substrate, we did not detect any significant differences in ROS 
production when knockout and wildtype mouse heart mitochondria were compared (Figure 
17), nor did we observe any differences when rotenone was added to inhibit complex I 
function. In the presence of antimycin A (AA), we observed a significant production of 
ROS. This is expected, as AA inhibits complex III leading to the production of ROS from 
this site. Interestingly, we observed a significant decrease in ROS production in the SphK2
-
/-
 mice compared to the wildtype mice when AA was used. When succinate was used as a 
substrate for complex II, again we observed no significant decrease in ROS production 
(Figure 17). When rotenone was used in this context to block reverse electron flow through 
complex I, we again observed a significant decrease in ROS production in the SphK2
-/-
 
mice compared to the wildtype mice.  
In a separate experiment, we evaluated the calcium retention capacity (CRC) of 
wildtype and SphK2
-/-
 mouse heart mitochondria (Figure 18). The CRC is an indicator of 
the state of the mitochondrial permeability transition pore (mPTP), which regulates the 
efflux of calcium from the mitochondria,  can open downstream of a wide variety of 
stimuli, and plays a role in apoptosis and cellular responses to various stresses (157,158).  
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Figure 17: Reactive oxygen species generation is decreased in SphK2
-/-
 mice. The 
generation of heart mitochondrial H2O2 from wildtype and SphK2
-/-
 mice was measured 
using both glutamate/malate and succinate as substrates for complex I and complex II, 
respectively. Data are expressed as means + SE. n = 2/group. Units are picomol H2O2/mg 
protein/30 minutes. None: baseline H2O2 production. ROT: H2O2 production in the 
presence of rotenone. AA: H2O2 production in the presence of antimycin A. N-R: None – 
rotenone (rotenone sensitive rate). *: p-value < 0.05.  
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Figure 18: Calcium retention capacity is unaltered in SphK2
-/-
 mitochondria. The 
release of calcium from intact heart mitochondria isolated from wildtype and SphK2
-/-
 
mice was measured in the presence or absence of cyclosporine A (CsA). Units are nmol 
calcium chloride/mg protein. n = 3.  
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This is of particular interest since many years ago it was suggested that intracellular 
S1P might regulate calcium mobilization (3,96,104,116-121) and prevent apoptosis 
(2,9,68,69). Because we observed a decrease in oxygen consumption in SphK2
-/-
 mice, we 
decided to investigate whether this decrease was due to a change in the CRC. We observed 
no difference in CRC between the two groups of mice (Figure 18). We also tested the CRC 
in the presence of cyclosporin A, an immunosuppressant known to block the opening of 
the mPTP (159), and again did not observe any difference in the mitochondrial CRC 
(Figure 18). 
Prohibitins have been demonstrated to assist in the assembly of the electron 
transport chain in mitochondria by binding subunits of respiratory complexes until they are 
fully assembled (151,153). Because we observed a defect in the oxygen consumption in 
SphK2
-/-
 mice, we next sought to determine if mitochondrial S1P generated by SphK2 
played any role in complex assembly. To this end, we employed blue native 
polyacrylamide gel electrophoresis (BN-PAGE), a technique that allows visualization of 
intact protein complexes, to analyze electron transport chain complex assembly in wildtype 
and SphK2
-/-
 mice. Intact mitochondria were lysed and equal amounts of protein were 
separated via BN-PAGE (Figure 19A), and intact electron transport chain complexes were 
identified based on molecular weight (indicated with arrows). In this experiment, we 
observed the presence of an extra band at approximately ~500kDa in the SphK2
-/-
 mice. 
Because we could not identify which complex this band belonged to based on MW, 
proteins were transferred to nitrocellulose membranes and probed with specific antibodies 
directed against subunits of all 4 complexes of the electron transport chain (Figure 19B). 
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Figure 19: SphK2
-/-
 display an aberrant complex IV via blue native page (BN-PAGE). 
Mouse mitochondrial proteins were isolated and separated on a pre-cast native PAGE gel 
(Invitrogen) and stained with Commassie Blue (panel A) or transferred to nitrocellulose 
and immunoblotted with the indicated antibodies against mitochondrial electron transport 
chain complexes (CI: complex I, CII: complex II, CIII: complex III, CIV: complex IV, 
CV: complex V). 
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In this experiment, we consistently observed what appeared to be an additional band of 
complex IV in the SphK2
-/-
 mitochondria.  
Prohibitins have also been demonstrated to assist in the maintenance of proper 
mitochondrial cristae morphology by interacting with and stabilizing optic atrophy protein 
I (OPA-1) in the inner mitochondrial membrane (160). In that study, inducible knockout of 
PHB2 in mouse embryonic fibroblasts led to ballooning of mitochondrial cristae. 
Furthermore, they demonstrated a decrease in oxygen consumption by complex IV, 
however their results were not statistically significant. To examine the possibility that S1P-
PHB2 interaction also plays a role in the maintenance of proper cristae morphology, we 
examined mitochondria from wildtype and SphK2
-/-
 mouse livers and hearts by electron 
microscopy. Both wildtype and SphK2
-/-
 mitochondria had normal appearing cristae in 
intact mouse myocardium (Figure 20). In liver sections, mitochondria from both WT and 
SphK2
-/-
 also had normal appearing cristae, however mitochondria in SphK2
-/-
 liver 
sections appeared smaller (Figure 21). In purified mitochondria from mouse livers, 
however, there was no visible difference in the size of mitochondria between WT and 
SphK2
-/-
 (Figure 22). Because these experiments were only conducted on one mouse from 
each group, more images must be obtained to determine if a genuine size discrepancy 
exists between the two groups of mice mitochondria. 
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Figure 20: Electron micrographs of wildtype and SphK2
-/-
 myocardium. Myocardial 
tissue was minced, fixed, and electron micrographs of both wildtype (WT) or SphK2
-/-
 
tissue were taken at 2000X and 20,000X.  
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Figure 21:  Electron micrographs of wildtype and SphK2
-/-
 liver sections. Whole livers 
were minced, fixed, and electron micrographs of both wildtype (WT) or SphK2
-/-
 tissue 
were taken at 2000X and 20,000X.  
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Figure 22: Electron micrographs of wildtype and SphK2
-/-
 purified liver 
mitochondria. Mitochondria from both wildtype (WT) or SphK2
-/-
 liver tissue were 
isolated, fixed, and electron micrographs of mitochondria were taken at 2000X and 5000X.  
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PHB2 has been shown to directly associate with subunits of cytochrome-c oxidase 
(complex IV) in mitochondria during their assembly (151,153). Therefore, we examined 
the possibility that this interaction may be impaired in SphK2
-/-
 mice with depleted levels 
of mitochondrial S1P. To this end, proteins co-immunoprecipitating with PHB2 from 
mitochondria were examined by immunoblotting with specific antibodies to complex IV 
and PHB2 (Figure 23).  As in previously published reports, we observed PHB2-complex 
IV interaction. Interestingly, this interaction was nearly ablated in SphK2
-/-
 mitochondria. 
This suggests that S1P may be important for PHB2 to exert its chaperone function in the 
mitochondria and potentially explains why we observe a deficit in oxygen consumption in 
SphK2
-/-
 mouse mitochondria.  
The observations that SphK2
-/-
 mice had lower S1P levels in mitochondria, 
impaired oxidative phosphorylation at complex IV, and an anomalous complex IV band on 
BN-PAGE led us to directly examine the enzymatic activity of complex IV in the presence 
or absence of exogenous S1P. Polarographic measurements of ADP-stimulated 
cytochrome-c oxidase (complex IV) were carried out in intact heart mitochondria from WT 
or SphK2
-/-
 supplemented with vehicle (BSA) or 10μM S1P (Figure 24). As we expected, 
SphK2
-/-
 mouse mitochondria displayed a decreased complex IV enzymatic activity. 
Strikingly, that activity returned to wildtype levels when mitochondria were pre-incubated 
with exogenous S1P (Figure 24). These results identify S1P, and not the presence of 
SphK2 alone, as the key element behind the observed respiratory defect in the knockout 
mitochondria.  
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Figure 23: PHB2-COXIV interaction is ablated in SphK2
-/-
 mouse myocardial 
mitochondria. Mitochondria were isolated from mouse hearts and lysed in IP buffer. 
Immunoprecipitation with PHB2 specific antibody was conducted and western blots for the 
indicated proteins was performed. Input = 1.0% total protein used in immunoprecipitation.  
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Figure 24: Cytochrome C oxidase activity is impaired in SphK2
-/-
 mice and can be 
restored with exogenous S1P. Maximally expressed cytochrome oxidase activity was 
measured using the polarographic method in mitochondria solubilized with deoxycholate 
(DOC) in the presence of 
32μM exogenous oxidized cytochrome c and either vehicle (fatty 
acid free BSA, 4mg/ml) or S1P (10μM). Values are means ± SE. Units are nanoatoms O . 
min
-1
 
.
 mg protein
-1
.  
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CHAPTER 4: Discussion 
 
 
4.1 Summary of Results 
 
In this study, we have demonstrated that intracellular S1P specifically interacts 
with prohibitin-2 (PHB2) in several different cell types. We demonstrated this using 
several techniques. First, PHB2 was specifically pulled down by S1P conjugated beads. 
PHB2 also specifically interacted with S1P immobilized on polystyrene plates, but not 
with other lipids. When nuclear extracts were incubated with [
32
P]S1P, 
immunoprecipitation of PHB2, but not control IgG or PHB1, resulted in co-
immunoprecipitation of [
32
P]S1P. Finally, endogenous S1P was also associated with 
immunoprecipitated PHB2 as analyzed by ESI/MS/MS.  PHB2-S1P interaction takes place 
in both the nucleus and mitochondria of cells, which are the two cellular compartments that 
prohibitins have been mainly localized to. In addition, we discovered that sphingosine 
kinase 2 (SphK2) is also localized in both the nucleus and mitochondria, and is responsible 
for the production of S1P that binds to PHB2. Depletion of SphK2 or knockout of SphK2 
significantly reduces levels of S1P in both the nucleus and mitochondria and reduces the 
amount of S1P bound to PHB2.  
In the nucleus, PHB2 acts as a repressor of transcription of E2 stimulated genes. 
When SphK2 was ectopically expressed in HeLa cells, the intranuclear concentration of 
S1P increased and E2 stimulated expression of GpGL3-2XERE-PS2-Luc, a reporter 
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construct with two estrogen response elements upstream from a luciferase gene,  was 
inhibited. A catalytically inactive SphK2 (SphK2
G212E
) did not inhibit this expression, 
indicating that formation of S1P was required for transcriptional repression.  Conversely, 
depletion of intranuclear S1P using siSphK2 augmented the transcription of ERE-
luciferase, but siSphK1, which only reduces cytosolic S1P levels and not nuclear S1P 
levels, did not. In MCF7 cells that endogenously express ERα, we observed a similar 
augmentation of the E2 responsive genes PS2 and cathepsin D when intranuclear S1P 
concentrations were depleted with siSphK2, while expression of cyclin D1, TYMS, 
CDC25A, and p27 was not significantly altered (data not shown). Interestingly, mRNA 
and protein levels of ERα were greatly reduced by siSphK2 as well as E2 in MCF7 cells, 
suggesting that S1P plays a direct role in modulating the expression of the ERα receptor 
itself. Finally, we observed a direct interaction between SphK2, PHB2, and HDAC1, 
suggesting that SphK2 and PHB2 may act in a repressor complex to inhibit E2-mediated 
gene transcription and that S1P generation itself plays a critical role in modulating that 
process. 
The majority of prohibitins are found in the mitochondria of most cell types. In our 
study, we localized both PHB1 and PHB2 to the mitochondria of mouse myocardial tissue, 
hepatocytes, human cervical cancer cells and human breast cancer cells. In addition, we 
also found SphK2 to be localized in mitochondria and knockout of SphK2 led to a 
substantial decrease in mitochondrial S1P levels, indicating that the enzyme is active in 
this cellular compartment. Furthermore, we demonstrate that PHB2 in the mitochondria is 
bound to S1P, and that depleting S1P levels in mitochondria leads to a subsequent decrease 
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in S1P bound PHB2. Prohibitins have a well documented chaperone-like function in the 
mitochondria and facilitate in the assembly of electron transport chain subunits, 
particularly those that make up cytochrome-c oxidase (COX, complex IV). Here we have 
demonstrated that depletion of mitochondrial S1P levels by SphK2 knockout leads to 
aberrant complex IV formation, decreased complex IV enzyme activity, and impaired 
oxygen consumption at complex IV. Our results do not preclude the possibility of other 
complex deficiencies and more studies are needed to investigate whether complex I or 
complex III assembly/enzymatic activity are also altered by SphK2 knockout, however 
they strongly suggest that S1P is necessary for proper electron transport chain assembly 
and function. These results suggest that S1P may be necessary for proper PHB2 function 
within the mitochondria. The exact mechanism by which S1P-PHB2 interaction facilitates 
mitochondrial PHB2 function has yet to be elucidated, and clearly more studies are 
indicated in this regard. 
 
4.2 Actions of Prohibitins 
 
Prohibitins (PHB1 and PHB2) are evolutionarily conserved proteins that are 
ubiquitously expressed in eukaryotic cells (153,161). The original discovery of prohibitins 
was made during a screen of genes in regenerating rat liver cells for potentially anti-
proliferative activity, thus the nomenclature “prohibitin” (162) was coined. Microinjection 
of the isolated prohibitin mRNA into normal human fibroblasts led to an inhibition of cell 
proliferation. It was later demonstrated that the 3’ untranslated region of the mRNA was 
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responsible for this antiproliferative effect (163). Prohibitin 2 was originally identified as a 
binding partner of the IgM isotype B-cell receptor plasma membrane protein, and was thus 
originally termed BAP37 for “B-cell receptor associated protein 37” (164). Subsequently, 
an independent group identified a protein that bound estrogen receptor alpha (ERα) and 
repressed its activity via a yeast-2-hybrid screen, which they named REA for “repressor of 
estrogen activity” (147). When this group cloned and sequenced REA, it was found to have 
an identical sequence to PHB2.  
 
4.3 Prohibitin Structure 
 
The prohibitins are members of a superfamily of proteins known as 
stomatin/flotillin/prohibitin/HflKC (153). PHB1 and PHB2 have a 53% amino acid 
sequence identity, and share a highly conserved structural domain known as the “prohibitin 
domain” or PHB domain. This domain is evolutionarily conserved across species, and is 
found in many proteins known to associate with lipids, lipid rafts, and plasma membranes 
(164-167). See Figure D from (168) for a schematic representation of both PHB1 and 
PHB2 and their assembly into heterodimers and ring-like supercomplexes. 
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Fig. D adapted from of (168). Prohibitins and their assembly into complexes. (A) 
Domain structures of mammalian prohibitins, including PHB domains (blue), hydrophobic 
stretches (grey), and coiled coil domains (purple) and their positions as indicated by amino 
acid number. (B) Dimers of PHB1 and PHB2 as building blocks of prohibitin complexes, 
which assemble into large ring-like supercomplexes. (C) The hydrophobic stretches of 
prohibitins anchor them in the mitochondrial membrane, exposing their carboxy termini to 
the intermembrane space (IMS). 
 
 
   
 94 
Both PHB1 and PHB2 sequences are nearly identical in humans and rodents, and 
PHB1 and PHB2 orthologues are found in yeast, plants, and flies (169,170). In humans, the 
PHB1 gene spans 11kb on chromosome 17q21 and is comprised of 7 exons, while the 
PHB2 gene is located on chromosome 12p13 and is comprised of 10 exons. For PHB1, 
there are untranslated regions (UTRs) spanning the first exon and part of the second, as 
well as the last 700bp of exon 7. A variety of transcripts of PHB1 containing different 
sized UTRs have been identified (171), with a greater abundance of longer transcripts 
present in dividing cells (172). In several studies, the abundance of PHB1 mRNA inversely 
corresponds to levels of many classic markers of cellular proliferation in a variety of cell 
types, providing more evidence that PHB1 is involved in cell cycle regulation (173-177). 
Of note, the most highly conserved regions between PHB1 and PHB2 contain the PHB 
domain. Both prohibitins contain C-terminal coiled-coil structures of alpha helices, 
mitochondrial targeting sequences (MTS), and nuclear localization sequences (NLS) (178). 
Additionally, some studies indicate that prohibitins can exist as phosphorylated or 
ubiquinated isoforms (147,179,180). 
 
4.4 Prohibitin Localization 
 
The majority of prohibitins are localized within the cell, although one study has 
demonstrated the presence of elevated prohibitin levels in the circulation of cancer patients 
(181). The mechanism of prohibitin release into the circulation is unknown, however 
prohibitins have been reported to associate with lipid droplets, which may be the 
   
 95 
mechanism by which they are released from cells (182). As PHB2 was originally 
discovered as a B-cell associated plasma membrane protein (164), the presence of 
prohibitins on the cell surface of other cell types is likely, as other proteins containing the 
PHB domain such as the stomatins and flotillins also localize at the plasma membrane 
(165,183,184).  
The vast majority of studies, however, focus on prohibitin localization in the 
nucleus and the mitochondria. Both prohibitins have been consistently detected in the 
nucleus of several different cell types (139,143,144,148,185,186). In addition, nuclear 
exportation of PHB1 in breast cancer cells in response to apoptotic stimuli has also been 
detected (144). This observation is not surprising, as PHB1 contains a nuclear export 
sequence (178). Interestingly, PHB2 contains both a nuclear localization sequence (NLS) 
at its C-terminus and a mitochondrial targeting sequence (MTS) at its N-terminus, and one 
study has demonstrated that PHB2 can shuttle back and forth between the mitochondria 
and nucleus (187).  
Immunohistochemical and cellular fractionation studies have demonstrated that in 
most cells, the majority of the PHB proteins are localized in the mitochondria 
(152,153,169,188-191), where PHB1 and PHB2 exist as large molecular weight complexes 
in the inner mitochondrial membrane (162,192,193). Hydrophobic stretches at the N-
terminal end of both prohibitins anchor them to the mitochondrial inner membrane, while 
long C-terminal carboxy stretches extend into the inner-membrane space (192). The 
presence of the C-terminal coiled-coil domain in both PHB1 and PHB2 has been 
demonstrated to be responsible for their heteromerization and stabilization, and depletion 
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of PHB1 or PHB2 mRNA with small interfering RNA (siRNA) leads to a reduction in both 
prohibitin protein levels despite specificity of each siRNA to downregulate its target 
sequence, suggesting that PHB1 protein stabilizes PHB2 protein and vice versa (150). 
Complete structural information of PHB1-PHB2 complexes does not exist, however in 
yeast one study has demonstrated that PHB1 and PHB2 form ring-like structures of 16-20 
alternating prohibitin molecules (192). The assembly of these complexes takes place inside 
the mitochondria, where PHB1 is imported and assembles with the Tim8/13 complex, a 
known mitochondrial chaperone that functions in the biogenesis of inner and outer 
membrane complexes (194). TIM23 translocase then mediates PHB1s insertion into the 
inner membrane, where it assembles with PHB2 into 120kD subunits, which then assemble 
into the large ring-like structures (192). No evidence has been obtained to demonstrate 
PHB1 or PHB2 homomers, suggesting that the heteromers are active biological structure 
inside the mitochondria. In addition to PHB1-PHB2 heteromers, there is increasing 
evidence that monomeric PHB1 or PHB2 also have specific biological functions beyond 
the proposed chaperone activity inside the inner mitochondrial membrane. In the nucleus, 
monomeric PHB1 and PHB2 have been shown to interact with a variety of transcriptional 
elements as well as the promoters of several genes (148,150), while in the mitochondria, 
monomeric PHB2 has been shown to interact with the anti-apoptotic protein Hax-1 present 
on the outer mitochondrial membrane (187). The pleiotropic location, structure, and 
function of the prohibitin molecules have been the subject of numerous recent studies, and 
while several major steps toward understanding the diverse roles of the prohibitins have 
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been taken, a completely clear picture of how the specific functions of PHB molecules are 
related to their cellular location has remained elusive. 
 
4.5 Prohibitin function within the nucleus 
 
In addition to being localized in the nucleus, many studies have demonstrated that 
both PHB1 and PHB2 interact with transcription factors, including ERα, HDAC1, Rb, p53, 
E2F, BRG1/BRM, Androgen Receptor, N-CoR, SRC-1, and Akt, and that these 
interactions play direct roles in modulating steroid hormone regulated transcription (140-
149). The mechanisms by which these proteins exert their transcriptional repression are 
controversial, and the way in which their repressive roles are regulated remain elusive. 
Here we review what has been published about prohibitins in the nucleus in the context of 
our own observed results. 
 
4.5.1 PHB1 in the nucleus 
 
In human breast cancer cell lines, PHB1 has been shown to co-localize with E2F1, 
pRB, and p53, and this interaction modulates E2F1 and p53 transcriptional activity (142-
144). The coiled-coil domain of PHB1 has been demonstrated to be crucial in PHB1’s 
interaction with both HDAC1 and E2F, and this region is sufficient to disrupt the pRb/E2F 
pathway and induce apoptosis when transfected into human cell lines (141). pRb and 
PHB1 interact with different regions of E2F1, since PHB1 mediated repression of E2F1 
   
 98 
transcription can be stimulated by signals that do not involve the pRb pathway (145). In 
addition, the region of E2F that is known to bind PHB1, termed the “marked-box,” is not 
involved in pRb repression of E2F1 transcription (140,145). HDAC1 activity may also be 
required for PHB1 to repress E2F1 mediated transcription, but without the involvement of 
other co-repressors like NCoR (140), and through an alternative pathway from pRb as 
E1A, p38 kinase, and cyclins D and E can reverse the pRb suppression of E2F1 
transcription while having no effect on the ability of PHB1 to repress transcription. In this 
same study, the authors demonstrated that PHB1 mediated suppression of E2F1 
transcription involved the recruitment of Brahma-related gene 1 (Brg-1) and Brm to E2F 
responsive promoters. These genes code for ATP-dependent enzymes in the SWI-SNF 
complex, which is responsible for chromatin remodeling during hormone-stimulated 
transcription. This complex has already been implicated in a pRb-independent pathway of 
E2F1 gene transcriptional repression (195) and in the transcriptional activation of estrogen 
receptor alpha (ERα) (196). In these studies, the authors demonstrate that estradiol (E2) 
binding of ERα and its subsequent translocation to the nucleus recruits Brg-1/Brm and 
facilitates chromatin remodeling, which leads to downstream transcription of several 
proteins that allow for progression through the cell cycle and lead to cellular proliferation. 
In addition, the same study demonstrated that depletion of PHB1 with siRNA blocks the 
anti-proliferative effects of the anti-estrogens tamoxifen and ICI in breast cancer cells. In 
addition, squelching the PHB1-E2F interaction by overexpressing a truncated E2F 
construct also blocked the effects of anti-estrogens. Taken together, these results strongly 
suggest that PHB1 is involved in mediating the effects of anti-estrogenic compounds.  
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4.5.2 PHB2 in the nucleus 
 
PHB2 is also a potent repressor of estrogen-mediated transcription. PHB2 was 
originally identified in a yeast-2-hybrid system using a dominant negative ERα as bait 
(147). It was originally named REA for “Repressor of Estrogen Activity,” as this initial 
study demonstrated that transfection of PHB2 into cells repressed estradiol-mediated gene 
expression in a ERE-Luciferase assay system. In addition, PHB2 potentiated the anti-
estrogenic effects of both anti-estrogen liganded ERα as well as dominant negative ERα 
expression. Transfection of PHB2 did not affect other steroid hormone receptor 
superfamily members, suggesting that the repressive effect of PHB2 is specific for E2-
mediated transcription. In this same study, the authors observed that the co-activator SRC-
1 could enhance ERα mediated transcriptional activity, and that PHB2 suppressed this 
enhancement in a dose dependent manner. The region of PHB2 that interacts with ERα is 
within the coiled-coil domain (197). PHB2 protein levels within human breast cancer 
biopsies have been shown to positively correlate with ERα levels and negatively correlate 
with tumor grade (198). Complete deletion of the PHB2 gene in mice results in embryonic 
lethality, but PHB2 -/+ mice are viable and display uterine hyperplasia, epithelial 
hyperproliferation, and an overall increased sensitivity to E2 treatment (149). This 
phenotype is in support of PHB2’s role as a suppressor of E2 transcription, as reduced 
levels of PHB2 in the nucleus, and hence a loss of E2 suppression, would lead to increased 
E2 sensitivity. This in vivo observation is of critical importance given the well documented 
efficacy of anti-estrogenic compounds in the treatment of human breast cancers (199).  
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A more recent study further characterized the roles of PHB1 and PHB2 in 
modulating E2-mediated transcription (150).  In this study, the authors overexpressed both 
PHB1 and PHB2 and showed that both proteins could repress E2-mediated transcription in 
an ERE-luciferase system. In addition, depletion of either PHB1 or PHB2 in MCF7 cells 
led to augmentation of E2-mediated expression of pS2 and cyclin D1. Importantly, the 
authors demonstrate that the co-repressor activity of PHB1 is cross-squelched by PHB2 
and vice versa, which the authors claim as evidence that both proteins only repress 
transcription when they are not paired and are in their monomeric state. Using chromatin 
immunoprecipitation (CHIP), they demonstrate the presence of PHB1 on the promoter of 
pS2. The heteromerization of PHB1 and PHB2 is dependent on the coiled-coil domain 
within each protein, and mutation of this region led to a loss of the cross-squelching ability 
of either protein. Finally, the generation of a PHB1 heterozygous knockout led mice with 
hyperproliferative mammary tissue. Taken together, this work provides some of the 
strongest evidence to date that PHB1 and PHB2 can act as monomeric transcription 
factors, and that their heteromerization with each other is a novel mechanism to limit this 
co-repressor activity. The mechanism by which this heteromerization-homomerization 
dynamic relationship is regulated has yet to be addressed, but given our results that S1P 
binds PHB2, but not PHB1, S1P production and PHB2-S1P binding being involved in this 
process is a compelling argument. Some of our initial studies where we added exogenous 
S1P to our immunoprecipitations of PHB1-PHB2 complexes appeared promising in that 
S1P seemed to decrease the degree of PHB1-PHB2 interaction, however these results were 
not readily reproducible and are therefore not included in this work. Again, this may have 
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been due to technical limitations, so more detailed studies of how S1P may modulate 
PHB1-PHB2 heteromerization are warranted. 
The precise mechanism by which PHB2 exerts repressive effects on gene 
transcription is controversial. Some studies have suggested that PHB2 binds directly to 
estrogen receptor alpha, displacing the coactivator SRC-1 from the receptor, thereby 
repressing E2-mediated gene transcription (147,165). Other studies have suggested that 
PHB2 can recruit histone deacetylases to E2 responsive promoters, facilitating the 
deacetylation of histones leading to transcriptional repression (139). Furthermore, two 
independent studies have suggested that the pool of prohibitins exists in the mitochondria, 
and that in the context of specific stimuli leave the mitochondria and migrate to the nucleus 
where they exert their transcriptional functions (187,200). In our studies, we confirmed 
that ectopic expression of PHB2 could repress E2-mediated gene transcription of an ERE-
luciferase reporter gene. Because this system is artificial and does not involve histone 
modifications, it supports the hypothesis that PHB2 can directly act on ERα itself. 
However, it should be noted that we were not able to demonstrate direct ERα-PHB2 
binding. This may be due to the limitations in the system we employed; we used standard 
immunoprecipitation techniques to pull down both PHB2 and ERα and immunoblotted for 
both these proteins. In the literature, all papers that have described ERα-PHB2 binding 
have either used in vitro translation to synthesize radiolabeled PHB2 or ERα, or have 
expressed GST-tagged PHB2 or ERα in bacteria (147,150,187), reviewed in (161). In 
addition, we were unable to reproduce the results of the one study (150) that demonstrated 
that depletion of PHB2 with siRNA augmented E2-mediated gene transcription, despite the 
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use of identical conditions, cell types, siRNAs, and several variations in protocol. In these 
experiments, we were able to reduce PHB2 mRNA by ~80%, but nuclear protein levels of 
PHB2 were only reduced by ~50%. It is possible that a ~50% reduction in PHB2 protein 
levels is insufficient to eliminate the repressive effects of PHB2 in regard to E2 
stimulation. Interestingly, in this same experiment, depleting S1P levels in the nucleus with 
siSphK2 did lead to an augmentation of E2-mediated gene transcription. It is therefore 
plausible that despite having adequate PHB2 levels in the nucleus for transcriptional 
repression of E2 stimulated genes, the lack of S1P-PHB2 interaction rendered PHB2 
unable to carry out its repressive function.  
Furthermore, we were unable to demonstrate mitochondrial PHB1 or PHB2 
migrating to the nucleus after E2 stimulation. This does not exclude the possibility that 
mitochondrial prohibitins migrate to the nucleus however, as a recent study demonstrated 
that in MCF7 cells, translocation of PHB2 to the nucleus required the repression brefeldin-
A-inhibited guanine nucleotide exchange protein 3 (BIG3) (201). Also, another study 
employed capsaicin to induce PHB2 translocation from mitochondria to the nucleus (200). 
Studies employing capsaicin as a stimulus and using siBIG3 to help facilitate nuclear 
PHB2 translocation are warranted in the context of either depletion or overexpression of 
SphK2 to further elucidate whether S1P can influence PHB2 translocation.  
Regardless of whether S1P can influence the accumulation of PHB2 in the nucleus, 
it is clear that nuclear S1P interacts with PHB2 and facilitates the repression of E2 
stimulated gene transcription. Taken together, these studies suggest a novel role for S1P in 
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the nucleus and warrant further study given the clinical importance of estrogen receptor 
expression and estrogen mediated gene transcription in a variety of breast cancers. 
 
 
 
Figure E: Potential model of S1P-PHB2 transcriptional repression of E2 stimulated 
genes. A: PHB1-PHB2 interaction in the nucleus prevents PHB2 from associating with 
ER/Co-activators, allowing E2 to stimulate gene transcription. Activation of SphK2 
produces S1P, which acts to dissociate PHB2 from PHB1, allowing PHB2 to interact with 
ERα and HDAC, repressing transcription. B: When E2 binds to ER, HDAC can act as a 
repressor. SphK2 can interact with HDAC, making S1P which inhibits HDAC and allows 
transcription to take place. When PHB2 is dissociated from PHB1, it can take the S1P 
away from HDAC, facilitating its interaction with ER and repressing transcription. 
A 
B 
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 4.6 Lipid signaling in the nucleus 
 
There is extensive evidence demonstrating that lipids have functions in the nucleus 
(202,203), adding to the feasibility of S1P having an intranuclear function. The most well 
studied of the nuclear lipids are the phosphoinositides. It is well known that 
phosphoinositides are generated in the cytosol following the activation of cell surface 
receptors via appropriate ligands and cause downstream second messenger generation. It 
was later discovered that nuclear phosphoinositide binding proteins were present within the 
nucleus, and may have other important roles such as mRNA splicing and the organization 
of chromatin (204). In addition, the nucleus has emerged as a site of active metabolism for 
a wide variety of lipids, and this metabolism is regulated independently from that of the 
plasma membrane (205). Lipids can function as second messengers within the nucleus, 
regulating cell proliferation and gene expression (206), and may also have direct functions 
in maintaining nuclear structure and regulating transcription (207). Phosphatidylinositols 
are ligands for the orphan receptor, steroidogenic factor 1 (SF-1) (208), which orchestrates 
endocrine development as well as sexual differentiation and steroid biosynthesis. SF-1 
bound phospholipid is readily exchanged and modulates SF-1 interaction with coactivators 
(209). Intranuclear lipid functions are not exclusive to PIPs; there is extensive evidence for 
active roles of other phospholipids in the nucleus of many cell types, including 
sphingomyelin (SM), phosphatidylserine (PS), phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylinositol (PI) phosphoinositide (PIP), 
plasmalogen (Plgs), and cholesterol.  
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The detection of SM and sphingomyelinase in the nucleus (210-212) and 
ceramidase (213,214) activities are of particular interest for two reasons. First, they 
indicate that nuclei have both the substrates and the enzymes that can generate 
sphingosine. Second, these reports indicate that ceramide/sphingosine is generated in the 
nucleus in a signal-mediated fashion, suggesting that the nucleus is not just a site for 
metabolic housekeeping. Moreover, several lines of evidence suggest that S1P may 
function in the nucleus. First, nuclear SphK activity increases as NIH cells enter S-phase, 
correlating with the translocation of SphK1 to the nuclear envelope (113). Second, SphK2 
has been localized inside the nucleus in several cell types, where its expression inhibited 
DNA synthesis (80). The effect of SphK2 on DNA synthesis was likely due to S1P 
production as directing SphK1 to the nucleus also inhibited DNA synthesis (80). Nuclear 
localization and inhibition of DNA synthesis were also correlated with SphK2-L 
overexpression, though SphK2-L translocated to the nucleus upon serum withdrawal rather 
than localizing there under steady-state conditions (71). Finally, it has also been shown that 
SphK2 has a nuclear export signal that can be activated by protein kinase D, suggesting a 
physiological role for nuclear S1P (115). Given the numerous reports of prohibitins 
functioning in the nucleus as transcriptional repressors, the observation that S1P binds to 
PHB2 in the nucleus and augments its repressive functions provides compelling evidence 
that S1P-PHB2 interaction may be a mechanism by which intranuclear S1P exerts many of 
these effects.  
4.7 Prohibitins in the mitochondria 
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The localization of prohibitins in the mitochondria has been clearly demonstrated. 
In yeast, prohibitins are essential for proper mitochondrial development. While PHB1 or 
PHB2 mutants in yeast have minimal phenotypes, these mutations in combination with 
several other mitochondrial proteins are lethal (152,215). In the mitochondrial inner 
membrane, prohibitins can assemble into large ring like super-complexes where they are 
believed to act as chaperones, protecting newly imported proteins from degradation 
(153,192). These complexes have been identified in various organisms and are composed 
of multiple copies of PHB1 and PHB2 (153,154,191). Several studies have noted that 
depletion or deletion of PHB1 or PHB2 leads to the loss of both prohibitin proteins, but the 
mRNA of the non-depleted prohibitin remains at normal levels (150,152,160,187,191), 
suggesting it is the physical stabilization of the prohibitin proteins with each other and not 
a transcription ally regulated event.  
The first studies claiming that prohibitins formed ring-like structures were 
hypothetical and based on the observations that prohibitins formed heteromers (169,216). 
Later, single particle electron microscopy yielded images of purified yeast prohibitins in 
ring-like complexes (192). It was later discovered that prohibitins are imported into the 
yeast mitochondria and associate with the Tim8/18 complex, followed by TIM23 mediated 
insertion into the inner mitochondrial membrane where they assemble into ring-like 
structures (192,194). 
Deletion of PHB2 impairs cell proliferation in yeast and mouse embryonic 
fibroblasts (160). In order to determine if this function was related to PHB2 in the nucleus 
or mitochondria, the authors designed a functional complementation assay to determine 
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whether mitochondrial targeting of PHB2 was the influencing factor regulating PHB2’s 
influence on proliferation. By mutating the non-cleavable mitochondrial targeting 
sequences, the authors were able to prevent mitochondrial targeting of PHB2 and halt cell 
proliferation. In contrast, mutations in the nuclear localization sequences of PHB2 had no 
influence on cellular proliferation. These results suggest that the mitochondrial targeting of 
PHB2 is essential for proper cell proliferation. Several studies have implicated intracellular 
S1P in cell growth, apoptosis, and calcium homeostasis (2,3,9,68,69,96,104,116-121), 
providing compelling evidence that the S1P-PHB2 interaction in mitochondria may have 
an important influence on how both S1P and PHB2 function in regulating proliferation. 
Mitochondria are dynamic structures that are constantly being remodeled by fusion 
and fission events (217,218). These events are tightly regulated by protein machinery in 
both the outer and inner mitochondrial membrane, including the dynamin-like GTPases 
mitofusin and OPA-1 (219,220). Detailed microscopic analysis of MEFs deficient in PHB2 
revealed defective cristae morphogenesis and the accumulation of vesicle-like structures 
and the absence of normal, lamellar-shaped cristae (160). These structural changes were 
attributed to the loss of OPA-1 and an increased susceptibility to apoptosis. A recent model 
has been proposed for OPA-1 in the maintenance of mitochondrial cristae junctions and the 
prevention of the release of cytochrome c into the intermembrane space, thus making cells 
more susceptible to apoptotic stimuli (221). In our study, we did not observe consistent 
degradation of OPA-1 in SphK2
-/-
 mouse heart or liver mitochondria (Figure 10), nor did 
we observe any cristae morphological changes in these tissues (Figures 20-21). This does 
not exclude the possibility that S1P is involved in the maintenance of OPA-1, because S1P 
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levels, although reduced in SphK2
-/-
 mitochondria, were still easily detectable (Figures 12 
and 14). Until both SphKs can be silenced simultaneously in mitochondria to completely 
deplete mitochondrial S1P, the precise role for S1P in the maintenance of cristae 
morphology will remain unanswered. In addition, MEF’s lacking PHB2 did not undergo 
apoptosis in the absence of apoptotic stimuli (160). Results from our laboratory have 
suggested that depletion of SphK2 in MCF7 cells rendered cells more susceptible to 
doxorubicin stimulated apoptosis (82). Because no apoptotic stimuli were used in this 
study, further experiments are indicated to examine whether PHB2 mediated maintenance 
of cristae morphology is disrupted or whether cells are more susceptible to apoptosis in 
SphK2
-/-
 MEFs when treated with doxorubicin or other apoptosis inducing agents. 
PHB1 and PHB2 have a sequence similarity to bacterial HflC and Hflk, which form 
a complex anchored to the plasma membrane oriented toward the perisplasmic space and 
functioned as a negative regulator of the AAA protease FtsH (222). This led to 
investigations as to whether PHB1 and PHB2 could function in mitochondrial enzyme 
processing (154). In this study, the authors demonstrated an association of the prohibitin 
complex with the mitochondrial AAA protease, leading to increased stability of 
mitochondrial translation products (151). In that study, the authors demonstrated using 
native electrophoresis and immunoprecipitation that the mitochondrial translation products 
Cox2p and Cox3p, subunits of cytochrome c oxidase (COX, electron transport chain 
complex IV), were associated with and stabilized by the prohibitin complex, and their 
aberrant assembly led to deficiencies in oxidative phosphorylation. In addition, the 
expression of the prohibitin complex was upregulated in mutants with other electron chain 
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subunit imbalances, such as mutations in the COX1-translation activator Mss51p or the 
COX assembly chaperone Shy1p (151,154). The human PHB complex is very similar to 
the yeast PHB complex and has been shown to have functions in regulating mitochondrial 
metabolism and is upregulated under certain metabolic stresses (169). This, coupled with 
the recent data showing the prohibitin complex’s crucial role in regulating mouse 
mitochondrial functions, strongly suggests that the chaperone-like functions that have been 
described in yeast are likely to be conserved in mammalian mitochondria.  
In our study, we reproduce the PHB2-COXIV binding results reported in (151) 
(Figure 23). Interestingly, this interaction seems to be inhibited in SphK2
-/-
 mitochondria 
that have significantly reduced S1P levels, suggesting that S1P may be function in the 
ability of the prohibitin complex ability to stabilize mitochondrial translation products.  
Furthermore, BN-PAGE experiments indicated that SphK2
-/-
 electron transport chains 
exhibited extra band in complex IV, which may represent a misfolded or improperly 
assembled complex (Figure 19).  When we analyzed oxidative phosphorylation in heart 
mitochondria from wildtype vs. SphK2
-/-
 mice, we found significantly reduced oxygen 
consumption by complex IV in the knockouts. This decrease in oxygen consumption 
correlated to a decrease in complex IV enzymatic activity (Figure 24), which, remarkably, 
appears to be rescued by the addition of exogenous S1P. Taken together, these results 
suggest that S1P has a novel function in the mitochondria by binding to PHB2 and 
facilitating its chaperone-like function in the assembly of electron transport chain 
complexes. 
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Figure F: Potential model for PHB2-S1P function in the assembly of electron 
transport chain subunits. The prohibitin complex exists as a ring-like structure imbedded 
in the inner membrane (IM). S1P produced by SphK2 interacts with PHB2 in the complex, 
facilitating the assembly of cytochrome c oxidase (COX), which leads to the pumping of 
hydrogen ions into the intermembrane space. The precise location of mitochondrial  SphK2 
is unknown. OM: outer membrane. 
 
 
4.8 Concluding remarks 
 
In this study, we have identified PHB2 as a novel binding partner for intracellular 
S1P. We have also demonstrated that S1P-PHB2 interaction modulates PHB2 function in 
both cellular compartments where it has a known function, the mitochondria and the 
nucleus. In the nucleus, PHB2 has been shown to be a repressor of E2-mediated gene 
transcription. Here we confirm this finding, and clearly show that SphK2 in the nucleus 
produces S1P, and that S1P-PHB2 binding augments this repressive effect. In the 
mitochondria, PHB2 and PHB1 have been shown to act as chaperones in the assembly of 
the electron transport chain, particularly cytochrome c oxidase (complex IV). Here we 
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show that SphK2 is also localized in the mitochondria and produces S1P, and we 
demonstrate that this S1P produced by SphK2 binds to PHB2. Furthermore, mice lacking 
SphK2 have significantly reduced mitochondrial S1P levels and display less S1P-PHB2 
interaction. Heart mitochondria isolated from SphK2
-/-
 mice have impaired oxygen 
consumption through complex IV, an aberrant assembly of complex IV, an impaired 
interaction of complex IV with PHB2, and a decreased enzymatic activity of complex IV 
that can be rescued with the addition of exogenous S1P. Taken together, these results 
strongly suggest that S1P-PHB2 interaction in the mitochondria is necessary for proper 
complex IV assembly and function. Due to their chaperone-like function in the 
mitochondria, more mitochondrial proteins are likely dependent on proper prohibitin 
complex function. Whether S1P will influence the proper assembly and folding of these 
newly discovered proteins should be investigated as it will point to a crucial function for 
S1P in a variety of diseases with mitochondrial pathophysiologies. 
While the evidence for PHB2-S1P interaction and function is compelling, there are 
still several questions that remained unanswered both by this work and in the literature. 
What is the relationship between PHB2 function in the nucleus vs. the mitochondria? Only 
two studies have tried to assess the possibility of shuttling of PHB2 between organelles 
(187,200). In the first study, the authors expressed flag-tagged PHB2 targeted to the 
mitochondria in HeLa cells, and found that they could induce movement from the 
mitochondria to the nucleus with E2 treatment. Using cyclohexamide to stop new protein 
synthesis, they proposed a model whereby PHB2 could shuttle back and forth between the 
organelles. The second study employed a similar approach using capsaicin to induce 
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nuclear translocation of mitochondrial PHB2. Both of these studies, however, employed 
artificial systems (overexpressing ERα, PHB2 tagged with a variety of epitopes, high 
concentrations of E2 or capsaicin, etc). This has led to some skepticism as to whether this 
movement is truly physiological (reviewed in (153)).  
Regardless of whether PHB2 moves from mitochondria to nucleus or whether the 
prohibitins exist as separate and independent pools, major questions about how PHB2 
function is regulated in both cell compartments remain unanswered. In the nucleus, PHB2 
and PHB1 can interact and cross squelch the transcriptional functions of each other (150). 
How is the dynamic balance between the inactive PHB1-2 heteromers and active 
monomers regulated? Our study has clearly demonstrated that only PHB2 and not PHB1 
interacts with S1P. What is the significance of this observation? Could S1P be involved in 
regulating this balance between heteromers and homomers, thus leading to our observed 
augmentation of PHB2 transcriptional repression? If so, that could also have direct 
applications in the mitochondria, where little is known about monomeric prohibitin 
function. It may be possible that the idea of a static PHB2-PHB1 ring complex is incorrect, 
and that individual subunits, as in the nucleus, can act independently of complex assembly. 
Finally, we believe that it is not coincidence that many of the phenotypes associated with 
intracellular production of S1P, namely response to stress, cell proliferation, regulation of 
gene transcription, and resistance to apoptosis are also phenotypes of proper PHB2 
function. The demonstration that S1P and PHB2 physically interact, and that this 
interaction has tangible effects on PHB2 function, may provide clues to the mechanisms 
behind these observations that have remained elusive for so many years.
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APPENDIX A: S1P binds to HDAC1 and HDAC2 
From: Sphingosine Kinase 2 and S1P in the Nucleus Regulate Histone Acetylation by 
Inhibition of Histone Deacetylases 
Nitai C. Hait, Jeremy Allegood, Michael Maceyka, Graham M. Strub, Kuzhuvelil 
B. Harikumar, Sandeep K. Singh, Cheng Luo, Ronen Marmorstein, Tomasz 
Kordula, Sheldon Milstien, Sarah Spiegel 
 
 
Appendix I: Nuclear extracts (NE) 
from MCF-7 cells were incubated with 
control, LPA, or S1P affinity matrices, 
as indicated, washed extensively and 
bound proteins resolved by SDS-
PAGE and then analyzed by Western 
blotting with anti-HDAC1 antibody or 
anti-HDAC2 antibody. 
 
Both HDAC1 and HDAC2 were pulled 
down by matrices carrying S1P but not 
by control or LPA matrices. In 
contrast, other class I HDACs 
(HDAC3, HDAC8), class IIa HDACs 
(HDAC4, HDAC5, HDAC7), and 
class IIb HDACs (HDAC6) or the 
NAD+-dependent protein deacetylase 
SIRT1 did not bind to S1P agarose 
beads. 
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